Opposite	O
effects	O
of	O
the	O
acute	B-protein
promyelocytic	I-protein
leukemia	I-protein
PML-retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
and	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
proteins	I-protein
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
and	O
the	O
PML	B-protein
or	O
PLZF	B-protein
nuclear	I-protein
protein	I-protein
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML-RAR	B-protein
alpha	I-protein
or	O
the	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML-RAR	B-protein
alpha	I-protein
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF-RAR	B-protein
alpha	I-protein
do	O
not	O
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML-RAR	B-protein
alpha	I-protein
expression	O
,	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	B-cell_line
and	O
HL-60	B-cell_line
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML-RAR	B-protein
alpha	I-protein
,	O
but	O
not	O
PLZF-RAR	B-protein
alpha	I-protein
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
and	O
restores	O
RA	O
sensitivity	O
of	O
RA-resistant	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
;	O
(	O
iii	O
)	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML-RAR	B-protein
alpha	I-protein
enhances	O
the	O
RA	O
response	O
of	O
RA	B-DNA
target	I-DNA
genes	I-DNA
(	O
those	O
for	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
and	O
transglutaminase	B-protein
type	I-protein
II	I-protein
[	O
TGase	B-protein
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF-RAR	B-protein
alpha	I-protein
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	B-protein
beta	I-protein
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	B-protein
gamma	I-protein
and	O
type	B-protein
II	I-protein
TGase	I-protein
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA-independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA-dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA-dependent	B-DNA
enhancers	I-DNA
or	O
inhibitors	O
of	O
RA-responsive	B-DNA
genes	I-DNA
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
contains	O
an	O
approximately	O
120-amino-acid	B-protein
N-terminal	I-protein
motif	I-protein
(	O
called	O
the	O
POZ	B-protein
domain	I-protein
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	B-protein
proteins	I-protein
and	O
which	O
mediates	O
protein-protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	B-protein
POZ	I-protein
domain	I-protein
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
on	O
RA-induced	O
differentiation	O
and	O
on	O
RA-mediated	O
type	B-protein
II	I-protein
TGase	I-protein
up-regulation	O
,	O
suggesting	O
that	O
POZ-mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Aug.	NULL
1997	NULL
,	NULL
p.	NULL
4859-4869	NULL
0270-7306/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

17	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Opposite	NULL
Effects	NULL
of	NULL
the	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
PML-Retinoic	NULL
Acid	NULL
Receptor	NULL
«	NULL
(	NULL
RAR	NULL
«	NULL
)	NULL
and	NULL
PLZF-RARa	NULL
Fusion	NULL
Proteins	NULL
on	NULL
Retinoic	NULL
Acid	NULL
Signalling	NULL
MARTIN	NULL
RUTHARDT	NULL
,	NULL
*	NULL
UGO	NULL
TESTA	NULL
,	NULL
CLARA	NULL
NERVI	NULL
,	NULL
*	NULL
PIER	NULL
FRANCESCO	NULL
FERRUCCL	NULL
,	NULL
*	NULL
FRANCESCO	NULL
GRIGNANI	NULL
,	NULL
!	NULL

ELENA	NULL
PUCCETTI	NULL
,	NULL
*	NULL
FAUSTO	NULL
GRIGNANTI	NULL
,	NULL
!	NULL

CESARE	NULL
PESCHLE	NULL
,	NULL
**	NULL
anp	NULL
PIER	NULL
GIUSEPPE	NULL
PELICCI~**	NULL
Department	NULL
of	NULL
Experimental	NULL
Oncology	NULL
,	NULL
European	NULL
Institute	NULL
of	NULL
Oncology	NULL
,	NULL
20141	NULL
Milan	NULL
,	NULL
``	NULL
Istituto	NULL
di	NULL
Medicina	NULL
Interna	NULL
e	NULL
Scienze	NULL
Oncologiche	NULL
,	NULL
Policlinico	NULL
Monteluce	NULL
,	NULL
Perugia	NULL
University	NULL
,	NULL
06100	NULL
Perugia	NULL
,	NULL
``	NULL
Department	NULL
of	NULL
Haematology	NULL
and	NULL
Oncology	NULL
,	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita	NULL
,	NULL
00161	NULL
Rome	NULL
,	NULL
``	NULL
and	NULL
Dipartmento	NULL
di	NULL
Istologia	NULL
ed	NULL
Embriologia	NULL
Medica	NULL
,	NULL
University	NULL
of	NULL
Rome	NULL
``	NULL
La	NULL
Sapienza	NULL
,	NULL
``	NULL
00161	NULL
Rome	NULL
,	NULL
``	NULL
Italy	NULL
,	NULL
and	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pennsylvania	NULL
19107-5541	NULL
``	NULL
Received	NULL
3	NULL
December	NULL
1996/Returned	NULL
for	NULL
modification	NULL
5	NULL
February	NULL
1997/Accepted	NULL
14	NULL
April	NULL
1997	NULL
Fusion	NULL
proteins	NULL
involving	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
(	NULL
RARa	NULL
«	NULL
)	NULL
and	NULL
the	NULL
PML	NULL
or	NULL
PLZF	NULL
nuclear	NULL
protein	NULL
are	NULL
the	NULL
genetic	NULL
markers	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemias	NULL
(	NULL
APLs	NULL
)	NULL
.	NULL

APLs	NULL
with	NULL
the	NULL
PML-RARa	NULL
«	NULL
or	NULL
the	NULL
PLZF-RARa	NULL
fusion	NULL
protein	NULL
are	NULL
phenotypically	NULL
indistinguishable	NULL
except	NULL
that	NULL
they	NULL
differ	NULL
in	NULL
their	NULL
sensitivity	NULL
to	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
-induced	NULL
differentiation	NULL
:	NULL
PML-RARa	NULL
«	NULL
blasts	NULL
are	NULL
sensitive	NULL
to	NULL
RA	NULL
and	NULL
patients	NULL
enter	NULL
disease	NULL
remission	NULL
after	NULL
RA	NULL
treatment	NULL
,	NULL
while	NULL
patients	NULL
with	NULL
PLZF-RARa	NULL
«	NULL
do	NULL
not	NULL
.	NULL

We	NULL
here	NULL
report	NULL
that	NULL
(	NULL
i	NULL
)	NULL
like	NULL
PML-RARa	NULL
«	NULL
expression	NULL
,	NULL
PLZEF-RARa	NULL
«	NULL
expression	NULL
blocks	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
(	NULL
U937	NULL
and	NULL
HL-60	NULL
)	NULL
in	NULL
response	NULL
to	NULL
different	NULL
stimuli	NULL
(	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
,	NULL
and	NULL
dimethyl	NULL
sulfoxide	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
PML-RARa	NULL
,	NULL
but	NULL
not	NULL
PLZF-RARa	NULL
,	NULL
increases	NULL
RA	NULL
sensitivity	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cells	NULL
and	NULL
restores	NULL
RA	NULL
sensitivity	NULL
of	NULL
RA-resistant	NULL
hematopoietic	NULL
cells	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
have	NULL
similar	NULL
RA	NULL
binding	NULL
affinities	NULL
;	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
PML-RARa	NULL
enhances	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
RA	NULL
target	NULL
genes	NULL
(	NULL
those	NULL
for	NULL
RARRB	NULL
,	NULL
RARy	NULL
,	NULL
and	NULL
transglutaminase	NULL
type	NULL
II	NULL
[	NULL
TGase	NULL
]	NULL
)	NULL
in	NULL
vivo	NULL
,	NULL
while	NULL
PLZF-RARa	NULL
«	NULL
expression	NULL
has	NULL
either	NULL
no	NULL
effect	NULL
(	NULL
RARf	NULL
)	NULL
or	NULL
an	NULL
inhibitory	NULL
activity	NULL
(	NULL
RARy	NULL
and	NULL
type	NULL
II	NULL
TGase	NULL
)	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
«	NULL
have	NULL
similar	NULL
(	NULL
inhibitory	NULL
)	NULL
effects	NULL
on	NULL
RA-independent	NULL
differentiation	NULL
and	NULL
opposite	NULL
(	NULL
stimulatory	NULL
or	NULL
inhibitory	NULL
)	NULL
effects	NULL
on	NULL
RA-dependent	NULL
differentiation	NULL
and	NULL
that	NULL
they	NULL
behave	NULL
in	NULL
vivo	NULL
as	NULL
RA-dependent	NULL
enhancers	NULL
or	NULL
inhibitors	NULL
of	NULL
RA-responsive	NULL
genes	NULL
,	NULL
respectively	NULL
.	NULL

Their	NULL
different	NULL
activities	NULL
on	NULL
the	NULL
RA	NULL
signalling	NULL
pathway	NULL
might	NULL
underlie	NULL
the	NULL
different	NULL
responses	NULL
of	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
«	NULL
APLs	NULL
to	NULL
RA	NULL
treatment	NULL
.	NULL

The	NULL
PLZF-RARa	NULL
«	NULL
fusion	NULL
protein	NULL
contains	NULL
an	NULL
approximately	NULL
120-amino-acid	NULL
N-terminal	NULL
motif	NULL
(	NULL
called	NULL
the	NULL
POZ	NULL
domain	NULL
)	NULL
,	NULL
which	NULL
is	NULL
also	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
zinc	NULL
finger	NULL
proteins	NULL
and	NULL
a	NULL
group	NULL
of	NULL
poxvirus	NULL
proteins	NULL
and	NULL
which	NULL
mediates	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
PLZF	NULL
POZ	NULL
domain	NULL
partially	NULL
abrogated	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
RA-induced	NULL
differentiation	NULL
and	NULL
on	NULL
RA-mediated	NULL
type	NULL
II	NULL
TGase	NULL
up-regulation	NULL
,	NULL
suggesting	NULL
that	NULL
POZ-mediated	NULL
protein	NULL
interactions	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
inhibitory	NULL
transcriptional	NULL
activities	NULL
of	NULL
PLZF-RARea	NULL
.	NULL

Acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
is	NULL
cytogenetically	NULL
characterized	NULL
by	NULL
a	NULL
reciprocal	NULL
translocation	NULL
that	NULL
always	NULL
involves	NULL
chromosome	NULL
17	NULL
,	NULL
with	NULL
a	NULL
break	NULL
within	NULL
the	NULL
locus	NULL
encoding	NULL
for	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
(	NULL
RARa	NULL
)	NULL
.	NULL

Chromosome	NULL
partners	NULL
are	NULL
chromosome	NULL
15	NULL
,	NULL
with	NULL
the	NULL
breakpoint	NULL
located	NULL
within	NULL
the	NULL
PML	NULL
locus	NULL
,	NULL
or	NULL
,	NULL
less	NULL
frequently	NULL
,	NULL
chromosome	NULL
11	NULL
,	NULL
with	NULL
the	NULL
breakpoint	NULL
within	NULL
the	NULL
PLZF	NULL
locus	NULL
(	NULL
15	NULL
,	NULL
51	NULL
)	NULL
.	NULL

The	NULL
hybrid	NULL
genes	NULL
so	NULL
formed	NULL
encode	NULL
a	NULL
PML-RARa	NULL
«	NULL
or	NULL
PLZF-RARa	NULL
«	NULL
fusion	NULL
protein	NULL
,	NULL
which	NULL
retain	NULL
equivalent	NULL
portions	NULL
of	NULL
RARa	NULL
(	NULL
5	NULL
,	NULL
10	NULL
,	NULL
22	NULL
,	NULL
24	NULL
,	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

The	NULL
15	NULL
;	NULL
17	NULL
and	NULL
11	NULL
;	NULL
17	NULL
translocations	NULL
are	NULL
primary	NULL
chromosome	NULL
aberrations	NULL
and	NULL
are	NULL
often	NULL
the	NULL
only	NULL
cytogenetic	NULL
anomalies	NULL
in	NULL
the	NULL
neoplastic	NULL
metaphases	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Experimental	NULL
evidence	NULL
for	NULL
leuke-mogenic	NULL
potential	NULL
,	NULL
however	NULL
,	NULL
is	NULL
available	NULL
only	NULL
for	NULL
PML-RARa	NULL
.	NULL

PML-RARa	NULL
blocks	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
(	NULL
14	NULL
,	NULL
16	NULL
)	NULL
,	NULL
and	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
mice	NULL
transgenic	NULL
for	NULL
PML-RARa	NULL
manifest	NULL
myeloid	NULL
differentiative	NULL
alterations	NULL
with	NULL
the	NULL
phenotypic	NULL
features	NULL
of	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
2a	NULL
,	NULL
18	NULL
)	NULL
.	NULL

*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
European	NULL
Institute	NULL
of	NULL
Oncology	NULL
,	NULL
Department	NULL
of	NULL
Experimental	NULL
Oncology	NULL
,	NULL
Via	NULL
Ripamonti	NULL
,	NULL
435	NULL
,	NULL
20141	NULL
Milan	NULL
,	NULL
Italy	NULL
.	NULL

Phone	NULL
:	NULL
39/2/57489	NULL
831	NULL
.	NULL

Fax	NULL
:	NULL
39/2/574	NULL
89/851	NULL
.	NULL

E-mail	NULL
:	NULL
pgpelicci	NULL
@	NULL
ieo.cilea.it	NULL
.	NULL

4859	NULL
Despite	NULL
the	NULL
fact	NULL
that	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
APLs	NULL
are	NULL
clinically	NULL
indistinguishable	NULL
,	NULL
they	NULL
differ	NULL
in	NULL
one	NULL
important	NULL
feature	NULL
:	NULL
their	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
.	NULL

PML-RARa	NULL
APL	NULL
blasts	NULL
are	NULL
highly	NULL
sensitive	NULL
to	NULL
RA	NULL
,	NULL
and	NULL
most	NULL
patients	NULL
treated	NULL
with	NULL
RA	NULL
achieve	NULL
disease	NULL
remission	NULL
(	NULL
9	NULL
,	NULL
20	NULL
,	NULL
33	NULL
,	NULL
50	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PLZF-RARa	NULL
«	NULL
-expressing	NULL
APLs	NULL
are	NULL
not	NULL
sensitive	NULL
to	NULL
RA	NULL
treatment	NULL
(	NULL
13	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
mechanisms	NULL
through	NULL
which	NULL
PML-RARa	NULL
«	NULL
blocks	NULL
differentiation	NULL
are	NULL
not	NULL
well	NULL
understood	NULL
.	NULL

The	NULL
cellular	NULL
localization	NULL
of	NULL
PML-RARa	NULL
is	NULL
anomalous	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
corresponding	NULL
wild-type	NULL
proteins	NULL
:	NULL
RARa	NULL
is	NULL
nuclear	NULL
diffuse	NULL
and	NULL
PML	NULL
is	NULL
localized	NULL
within	NULL
specific	NULL
subnuclear	NULL
structures	NULL
called	NULL
PML	NULL
nuclear	NULL
bodies	NULL
,	NULL
whereas	NULL
PML-RARa	NULL
has	NULL
a	NULL
distinct	NULL
nuclear	NULL
distribution	NULL
pattern	NULL
(	NULL
microspeckled	NULL
localization	NULL
)	NULL
(	NULL
12	NULL
,	NULL
27	NULL
,	NULL
52	NULL
)	NULL
.	NULL

It	NULL
was	NULL
initially	NULL
proposed	NULL
that	NULL
PML-RARa	NULL
exerts	NULL
a	NULL
dominant-negative	NULL
action	NULL
on	NULL
wild-type	NULL
PML	NULL
and	NULL
RXR	NULL
,	NULL
an	NULL
RARa	NULL
cofactor	NULL
(	NULL
26	NULL
,	NULL
53	NULL
,	NULL
54	NULL
)	NULL
,	NULL
in	NULL
that	NULL
expression	NULL
of	NULL
PML-RARa	NULL
«	NULL
provokes	NULL
PML	NULL
and	NULL
RXR	NULL
delocalization	NULL
within	NULL
microspeckles	NULL
(	NULL
12	NULL
,	NULL
27	NULL
,	NULL
44	NULL
,	NULL
52	NULL
)	NULL
.	NULL

This	NULL
hypoth-esis	NULL
,	NULL
however	NULL
,	NULL
has	NULL
been	NULL
recently	NULL
challenged	NULL
by	NULL
the	NULL
demonstration	NULL
that	NULL
delocalization	NULL
of	NULL
neither	NULL
PML	NULL
nor	NULL
RXR	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
action	NULL
of	NULL
PML-RARa	NULL
«	NULL
on	NULL
differentiation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Nothing	NULL
is	NULL
known	NULL
about	NULL
the	NULL
biological	NULL
activity	NULL
or	NULL
cellular	NULL
localization	NULL
of	NULL
the	NULL
PLZF-RARa	NULL
fusion	NULL
protein	NULL
.	NULL

4860	NULL
RUTHARDT	NULL
ET	NULL
AL	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
of	NULL
the	NULL
APL	NULL
response	NULL
to	NULL
RA	NULL
remain	NULL
unclear	NULL
.	NULL

Some	NULL
investigators	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
principal	NULL
effect	NULL
of	NULL
RA	NULL
is	NULL
that	NULL
it	NULL
releases	NULL
the	NULL
dominant-negative	NULL
effect	NULL
of	NULL
PML-RARa	NULL
on	NULL
wild-type	NULL
PML	NULL
or	NULL
RXR	NULL
,	NULL
thereby	NULL
removing	NULL
the	NULL
inhibitory	NULL
activity	NULL
on	NULL
differentiation	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
RA	NULL
treatment	NULL
of	NULL
APL	NULL
blasts	NULL
induces	NULL
progressive	NULL
disappearance	NULL
of	NULL
the	NULL
PML-RARa	NULL
microspeckles	NULL
and	NULL
the	NULL
reorganization	NULL
of	NULL
PML	NULL
nuclear	NULL
bodies	NULL
and	NULL
,	NULL
as	NULL
a	NULL
consequence	NULL
,	NULL
restores	NULL
the	NULL
physiological	NULL
localization	NULL
of	NULL
PML	NULL
and	NULL
RXR	NULL
(	NULL
12	NULL
,	NULL
27	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Others	NULL
instead	NULL
propose	NULL
that	NULL
PML-RARa	NULL
microspeckles	NULL
are	NULL
actively	NULL
involved	NULL
in	NULL
conferring	NULL
sensitivity	NULL
to	NULL
RA	NULL
and	NULL
hypothesize	NULL
that	NULL
PMLRARa	NULL
exerts	NULL
a	NULL
direct	NULL
effect	NULL
on	NULL
RA	NULL
signalling	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RA	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
RA	NULL
on	NULL
the	NULL
PLZF-RARa	NULL
protein	NULL
are	NULL
unknown	NULL
,	NULL
and	NULL
the	NULL
only	NULL
available	NULL
data	NULL
refers	NULL
to	NULL
the	NULL
in	NULL
vitro	NULL
transactivating	NULL
activity	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
cloned	NULL
RA	NULL
target	NULL
genes	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
PML-RARa	NULL
(	NULL
6	NULL
)	NULL
.	NULL

We	NULL
expressed	NULL
PLZF-RARa	NULL
in	NULL
various	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
and	NULL
analyzed	NULL
its	NULL
effects	NULL
on	NULL
terminal	NULL
differentiation	NULL
and	NULL
RA	NULL
target	NULL
genes	NULL
,	NULL
both	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
pharmacological	NULL
doses	NULL
of	NULL
RA	NULL
,	NULL
and	NULL
compared	NULL
the	NULL
results	NULL
with	NULL
those	NULL
obtained	NULL
with	NULL
PML-RARa	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
background	NULL
.	NULL

The	NULL
comparison	NULL
provided	NULL
information	NULL
essential	NULL
for	NULL
understanding	NULL
the	NULL
mechanisms	NULL
at	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
differentiation	NULL
block	NULL
in	NULL
APL	NULL
blasts	NULL
,	NULL
as	NULL
well	NULL
as	NULL
their	NULL
response	NULL
to	NULL
RA	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Preparation	NULL
of	NULL
PLZF	NULL
,	NULL
PLZF-RARa	NULL
«	NULL
,	NULL
and	NULL
POZ-PLZEF-RARa	NULL
«	NULL
expression	NULL
vec-tors	NULL
.	NULL

PLZF	NULL
cDNA	NULL
clones	NULL
were	NULL
isolated	NULL
from	NULL
a	NULL
cDNA	NULL
library	NULL
of	NULL
KG1	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
(	NULL
Clontech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
Calif.	NULL
)	NULL
by	NULL
using	NULL
a	NULL
DNA	NULL
probe	NULL
representative	NULL
of	NULL
the	NULL
human	NULL
PLZF	NULL
POZ	NULL
domain	NULL
,	NULL
according	NULL
to	NULL
standard	NULL
screening	NULL
protocols	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
PLZF-POZ	NULL
DNA	NULL
probe	NULL
was	NULL
synthesized	NULL
from	NULL
total	NULL
RNA	NULL
from	NULL
KG1	NULL
cells	NULL
by	NULL
reverse	NULL
transcription-PCR	NULL
with	NULL
the	NULL
PLZF1	NULL
(	NULL
5	NULL
AAGCCTCATGCCTGA	NULL
GCCGA3F	NULL
'	NULL
)	NULL
and	NULL
PLZF2	NULL
(	NULL
§STACTCGATCTCCAGGATCTC3	NULL
'	NULL
)	NULL
oligonucleo-tides	NULL
.	NULL

Of	NULL
cight	NULL
isolated	NULL
cDNAs	NULL
,	NULL
one	NULL
contained	NULL
the	NULL
full-length	NULL
open	NULL
reading	NULL
frame	NULL
of	NULL
PLZF	NULL
(	NULL
clone	NULL
4B	NULL
)	NULL
.	NULL

It	NULL
was	NULL
61	NULL
bp	NULL
longer	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
than	NULL
the	NULL
reported	NULL
PLZF	NULL
B	NULL
cDNA	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
PLZF-RARa	NULL
cDNA	NULL
was	NULL
reconstructed	NULL
by	NULL
PCR	NULL
from	NULL
wild-type	NULL
PLZF	NULL
and	NULL
RARa	NULL
cDNAs	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
PLZF	NULL
fragment	NULL
was	NULL
amplified	NULL
from	NULL
position	NULL
1446	NULL
(	NULL
corresponding	NULL
to	NULL
the	NULL
Sacl	NULL
site	NULL
)	NULL
to	NULL
position	NULL
1522	NULL
(	NULL
corresponding	NULL
to	NULL
the	NULL
PLZF-RARa	NULL
crossover	NULL
junction	NULL
)	NULL
(	NULL
5'TITG	NULL
GCACCCCGGGAATGAGCCAGTAY	NULL
'	NULL
)	NULL
so	NULL
that	NULL
a	NULL
Smel	NULL
site	NULL
(	NULL
underlined	NULL
)	NULL
was	NULL
inserted	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
PLZF	NULL
fragment	NULL
.	NULL

A	NULL
similar	NULL
strategy	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
an	NULL
RARa	NULL
fragment	NULL
from	NULL
the	NULL
PML	NULL
junction	NULL
point	NULL
(	NULL
5ATCCCCAGCC	NULL
CGGGTTGAGACCCAGA3	NULL
'	NULL
)	NULL
to	NULL
the	NULL
Sect	NULL
site	NULL
of	NULL
RARe	NULL
(	NULL
5'TTGCGCACCIT	NULL
CTCAATGAGCTC3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
PLZF-RARa	NULL
junction	NULL
was	NULL
then	NULL
reconstructed	NULL
by	NULL
Smal	NULL
ligation	NULL
of	NULL
the	NULL
two	NULL
fragments	NULL
.	NULL

Since	NULL
the	NULL
Smal	NULL
site	NULL
used	NULL
to	NULL
generate	NULL
the	NULL
PLZF-RARa	NULL
«	NULL
junction	NULL
introduced	NULL
a	NULL
novel	NULL
amino	NULL
acid	NULL
,	NULL
the	NULL
appropriate	NULL
junction	NULL
was	NULL
reconstructed	NULL
by	NULL
PCR-based	NULL
mutagenesis	NULL
(	NULL
5°CGGGTGCGAGCTCGCGG	NULL
GA3	NULL
'	NULL
,	NULL
and	NULL
5'TTGCGCACCITTCTCA	NULL
ATGAGCTC3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
newly	NULL
generated	NULL
PLZF-RARa	NULL
fragment	NULL
was	NULL
then	NULL
ligated	NULL
to	NULL
the	NULL
appropriate	NULL
RARa	NULL
sequences	NULL
to	NULL
generate	NULL
a	NULL
full-length	NULL
PLZF-RARa	NULL
cDNA	NULL
.	NULL

To	NULL
generate	NULL
the	NULL
POZ-PLZF-RARa	NULL
mutant	NULL
,	NULL
the	NULL
POZ	NULL
domain-encoding	NULL
sequence	NULL
(	NULL
nucleotides	NULL
1	NULL
to	NULL
471	NULL
)	NULL
of	NULL
PLZF-RARa	NULL
was	NULL
replaced	NULL
,	NULL
by	NULL
PCR	NULL
,	NULL
with	NULL
a	NULL
sequence	NULL
encoding	NULL
a	NULL
translational	NULL
initiation	NULL
site	NULL
.	NULL

The	NULL
5	NULL
'	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
translational	NULL
initiation	NULL
site	NULL
was	NULL
5AGATCCTGGAGATCGCCACCAT	NULL
GGAGGAACAGTGCCTGA3	NULL
'	NULL
.	NULL

All	NULL
of	NULL
the	NULL
DNA	NULL
fragments	NULL
generated	NULL
by	NULL
PCR	NULL
were	NULL
controlled	NULL
by	NULL
DNA	NULL
sequence	NULL
.	NULL

The	NULL
PLZF	NULL
,	NULL
PLZF-RARa	NULL
,	NULL
and	NULL
POZ-PLZF-RARa	NULL
cDNAs	NULL
so	NULL
obtained	NULL
were	NULL
subcloned	NULL
into	NULL
the	NULL
pGMTSVneo	NULL
Zn-inducible	NULL
expression	NULL
vector	NULL
(	NULL
14	NULL
)	NULL
and	NULL
the	NULL
adenovirus-based	NULL
PMT2	NULL
expression	NULL
vector	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
preparation	NULL
of	NULL
the	NULL
hemagglutinin-tagged	NULL
PML-RARa	NULL
expression	NULL
vector	NULL
has	NULL
been	NULL
already	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
anti-PLZF	NULL
antibodies	NULL
.	NULL

The	NULL
PLZF	NULL
open	NULL
reading	NULL
frame	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
bacterial	NULL
expression	NULL
plasmid	NULL
pGEX-2T	NULL
after	NULL
PCR-based	NULL
creation	NULL
of	NULL
an	NULL
in-frame	NULL
BamHI	NULL
site	NULL
corresponding	NULL
to	NULL
the	NULL
first	NULL
ATG	NULL
of	NULL
PLZF	NULL
.	NULL

Bacterial	NULL
cultures	NULL
expressing	NULL
pGEX	NULL
vectors	NULL
were	NULL
grown	NULL
in	NULL
Luria	NULL
broth	NULL
containing	NULL
50	NULL
ug	NULL
of	NULL
ampicillin	NULL
per	NULL
ml	NULL
and	NULL
induced	NULL
with	NULL
1	NULL
mM	NULL
IPTG	NULL
(	NULL
isopropyl-B-o-thiogalactopyr-anoside	NULL
)	NULL
for	NULL
3	NULL
to	NULL
6	NULL
h	NULL
,	NULL
and	NULL
the	NULL
induced	NULL
bacteria	NULL
were	NULL
lysed	NULL
by	NULL
sonication	NULL
in	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

The	NULL
glutathione	NULL
S-transferase-PLZF	NULL
fusion	NULL
protein	NULL
was	NULL
purified	NULL
by	NULL
using	NULL
glutathione-agarose	NULL
and	NULL
eluted	NULL
with	NULL
15	NULL
mM	NULL
glutathione	NULL
.	NULL

Anti-PLZF	NULL
antibodies	NULL
were	NULL
prepared	NULL
by	NULL
immunizing	NULL
New	NULL
Zealand	NULL
White	NULL
rabbits	NULL
with	NULL
the	NULL
purified	NULL
glutathione	NULL
S-transferase-PLZF	NULL
fusion	NULL
protein	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
anti-PLZF	NULL
antibody	NULL
was	NULL
tested	NULL
on	NULL
COS-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
PLZF	NULL
expression	NULL
vector	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

Cell	NULL
culture	NULL
,	NULL
transfection	NULL
,	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

U937	NULL
cells	NULL
,	NULL
HL60	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
RA-resistant	NULL
HL60	NULL
subclone	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
S.	NULL
Collins	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

After	NULL
electropo-ration	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
selected	NULL
in	NULL
G418	NULL
and	NULL
subcloned	NULL
under	NULL
limiting-dilution	NULL
conditions	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
exogenous	NULL
protein	NULL
was	NULL
evaluated	NULL
by	NULL
Western	NULL
blotting	NULL
after	NULL
6	NULL
to	NULL
12	NULL
h	NULL
of	NULL
induction	NULL
with	NULL
100	NULL
wM	NULL
ZnSQ	NULL
,	NULL
,	NULL
using	NULL
an	NULL
anti-RARa	NULL
«	NULL
-F	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
P.	NULL
Chambon	NULL
)	NULL
or	NULL
the	NULL
anti-PLZF	NULL
antibodies	NULL
,	NULL
according	NULL
to	NULL
established	NULL
procedures	NULL
.	NULL

Cell	NULL
differentiation	NULL
experiments	NULL
and	NULL
analysis	NULL
of	NULL
cell	NULL
phenotype	NULL
.	NULL

Experiments	NULL
involving	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
dihydroxy-vitamin	NULL
D	NULL
,	NULL
(	NULL
D3	NULL
)	NULL
and	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
(	NULL
TGF	NULL
)	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
differentiation	NULL
antigen-positive	NULL
cells	NULL
and	NULL
fluorescence	NULL
intensity	NULL
were	NULL
evaluated	NULL
by	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
with	NULL
appropriate	NULL
antibodies	NULL
(	NULL
14	NULL
,	NULL
17	NULL
)	NULL
.	NULL

RA-induced	NULL
differentiation	NULL
was	NULL
investigated	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

For	NULL
HL-60	NULL
and	NULL
HL-60R	NULL
cells	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
107°	NULL
M	NULL
RA	NULL
,	NULL
1.25	NULL
%	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
,	NULL
or	NULL
250	NULL
ng	NULL
of	NULL
D3	NULL
per	NULL
ml	NULL
.	NULL

Granulocytic	NULL
and	NULL
monocytic	NULL
differentiation	NULL
was	NULL
evaluated	NULL
by	NULL
(	NULL
i	NULL
)	NULL
flow	NULL
cytometry	NULL
analysis	NULL
of	NULL
differentiation-related	NULL
surface	NULL
antigens	NULL
with	NULL
appropriate	NULL
antibodies	NULL
(	NULL
see	NULL
Results	NULL
)	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
light	NULL
microscopy	NULL
observation	NULL
of	NULL
May-Griinwald-Giemsa-stained	NULL
samples	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
and	NULL
TGase	NULL
assay	NULL
.	NULL

Total	NULL
and	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
samples	NULL
(	NULL
10	NULL
ug	NULL
each	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
Northern	NULL
blotting	NULL
according	NULL
to	NULL
established	NULL
procedures	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
RARB	NULL
probe	NULL
was	NULL
the	NULL
Secl/BamHI	NULL
restriction	NULL
fragment	NULL
of	NULL
the	NULL
recombinant	NULL
PSGS	NULL
RARB	NULL
vector	NULL
,	NULL
the	NULL
RARy	NULL
probe	NULL
was	NULL
the	NULL
BemHI	NULL
restriction	NULL
fragment	NULL
of	NULL
the	NULL
recombinant	NULL
PSGS	NULL
RARy	NULL
cDNA	NULL
clone	NULL
,	NULL
and	NULL
the	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
probe	NULL
was	NULL
the	NULL
Psfl	NULL
cDNA	NULL
fragment	NULL
of	NULL
the	NULL
rat	NULL
GAPDH	NULL
plasmid	NULL
.	NULL

TGase	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
soluble	NULL
cell	NULL
fractions	NULL
by	NULL
measuring	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
*H	NULL
}	NULL
putrescine	NULL
(	NULL
12.6	NULL
Ci/mmol	NULL
;	NULL
Amersham	NULL
Corp.	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IIL	NULL
.	NULL
)	NULL

into	NULL
casein	NULL
in	NULL
triplicate	NULL
cultures	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
2	NULL
)	NULL
.	NULL

RA	NULL
binding	NULL
assays	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
with	NULL
a	NULL
pSGS	NULL
expression	NULL
vector	NULL
for	NULL
RARa	NULL
«	NULL
or	NULL
PML-RARa	NULL
or	NULL
with	NULL
a	NULL
pMT2	NULL
expression	NULL
vector	NULL
for	NULL
PLZF-RARa	NULL
.	NULL

At	NULL
48	NULL
to	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
transfected	NULL
COS-1	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
39	NULL
)	NULL
.	NULL

For	NULL
saturation	NULL
binding	NULL
and	NULL
Scatchard	NULL
analyses	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
for	NULL
18	NULL
h	NULL
at	NULL
4°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
concentrations	NULL
(	NULL
0.01	NULL
to	NULL
20	NULL
nM	NULL
)	NULL
of	NULL
°H-labelled	NULL
all-frans-retinoic	NULL
acid	NULL
(	NULL
t-RA	NULL
)	NULL
(	NULL
50.7	NULL
Ci/mmol	NULL
;	NULL
DuPont/	NULL
NEN	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

Nonspecific	NULL
binding	NULL
activity	NULL
was	NULL
measured	NULL
at	NULL
each	NULL
time	NULL
point	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
t-RA	NULL
.	NULL

Specific	NULL
ligand	NULL
binding	NULL
to	NULL
receptors	NULL
was	NULL
separated	NULL
from	NULL
free	NULL
radioactivity	NULL
by	NULL
using	NULL
PD10	NULL
desalting	NULL
columns	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Linear	NULL
least-squares	NULL
analysis	NULL
of	NULL
the	NULL
Scatchard	NULL
plot	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
aid	NULL
of	NULL
the	NULL
computer	NULL
program	NULL
BDATA-EMF	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
PLZF-RARa	NULL
blocks	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
U937	NULL
and	NULL
HL-60	NULL
precursor	NULL
cell	NULL
lines	NULL
induced	NULL
by	NULL
D3-TGF	NULL
or	NULL
DMSO	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
PLZF-RARa	NULL
blocks	NULL
terminal	NULL
differentiation	NULL
in	NULL
vitro	NULL
,	NULL
the	NULL
PLZF-RARa	NULL
cDNA	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
HL-60	NULL
and	NULL
U937	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
their	NULL
potential	NULL
to	NULL
undergo	NULL
terminal	NULL
differentiation	NULL
was	NULL
analyzed	NULL
.	NULL

The	NULL
promonocytic	NULL
U937	NULL
cells	NULL
proceed	NULL
towards	NULL
terminal	NULL
differentiation	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
250	NULL
ng	NULL
of	NULL
D3	NULL
per	NULL
ml	NULL
and	NULL
1	NULL
ng	NULL
of	NULL
TGF	NULL
per	NULL
ml	NULL
(	NULL
48	NULL
)	NULL
.	NULL

The	NULL
myeloblastic	NULL
HL-60	NULL
cells	NULL
differentiate	NULL
towards	NULL
the	NULL
granulocytic	NULL
line	NULL
when	NULL
induced	NULL
with	NULL
DMSO	NULL
and	NULL
towards	NULL
the	NULL
monocytic	NULL
line	NULL
when	NULL
stimulated	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
D3	NULL
and	NULL
TGF	NULL
(	NULL
7	NULL
,	NULL
48	NULL
)	NULL
.	NULL

The	NULL
PLZF-RARa	NULL
cDNA	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Zn-inducible	NULL
MT-1	NULL
promoter	NULL
was	NULL
electroporated	NULL
into	NULL
U937	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

After	NULL
G418	NULL
selection	NULL
and	NULL
limiting	NULL
dilution	NULL
,	NULL
8	NULL
of	NULL
15	NULL
U937	NULL
clones	NULL
and	NULL
5	NULL
of	NULL
12	NULL
HL-60	NULL
clones	NULL
were	NULL
positive	NULL
for	NULL
PLZF-RARa	NULL
expression	NULL
by	NULL
Western	NULL
blotting	NULL
analysis	NULL
with	NULL
anti-PLZF	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
or	NULL
anti-RARa	NULL
antibodies	NULL
.	NULL

Two	NULL
clones	NULL
of	NULL
each	NULL
cell	NULL
type	NULL
were	NULL
selected	NULL
for	NULL
further	NULL
analysis	NULL
by	NULL
two	NULL
criteria	NULL
:	NULL
(	NULL
i	NULL
)	NULL
increased	NULL
protein	NULL
expression	NULL
upon	NULL
Zn	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
capacity	NULL
to	NULL
undergo	NULL
terminal	NULL
differentiation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Zn	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
U937	NULL
clones	NULL
that	NULL
were	NULL
analyzed	NULL
revealed	NULL
a	NULL
slight	NULL
PLZF-RARa	NULL
expression	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Zn	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
;	NULL
however	NULL
,	NULL
this	NULL
level	NULL
of	NULL
Zn-independent	NULL
fusion	NULL
protein	NULL
expression	NULL
did	NULL
not	NULL
interfere	NULL
significantly	NULL
with	NULL
differentiation	NULL
induced	NULL
by	NULL
D3-TGF	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Clones	NULL
transfected	NULL
with	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL

Vou	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
EFFECTS	NULL
OF	NULL
PML-RARe	NULL
AND	NULL
PLZF-RARa	NULL
«	NULL
ON	NULL
RA	NULL
DIFFERENTIATION	NULL
-	NULL
4861	NULL
U937	NULL
HL-60	NULL
A	NULL
T	NULL
i	NULL
MT	NULL
PLZF/RARa	NULL
__	NULL
PML/RARa	NULL
MT	NULL
PLZF/RARa	NULL
sas	NULL
-	NULL
Baiz	NULL
'	NULL
Pro	NULL
``	NULL
B31	NULL
``	NULL
B2s	NULL
B211	NULL
Zn	NULL
-	NULL
TOI	NULL
]	NULL
I	NULL
CEA	NULL
,	NULL
;	NULL
TGI	NULL
O71	NULL
200	NULL
=	NULL
--	NULL
PML/RARa	NULL
puzrirarl	NULL
'	NULL
E=	NULL
seats	NULL
97	NULL
=	NULL
66	NULL
j	NULL
RARa	NULL
B	NULL
HL-6OR	NULL
I	NULL
MT	NULL
PLZF/RARa	NULL
PML/RARa	NULL
I	NULL
I	NULL
wan	NULL
#	NULL
340	NULL
#	NULL
42	NULL
``	NULL
#	NULL
121	NULL
#	NULL
131	NULL
Zn	NULL
+	NULL
7+	NULL
I	NULL
+1	NULL
200	NULL
=	NULL
--	NULL
PML/RARa	NULL
PLZF/RARe	NULL
!	NULL

&	NULL
=	NULL
a	NULL
97	NULL
=	NULL
66	NULL
j	NULL
RARa	NULL
C	NULL
HL-6OR	NULL
U937	NULL
PLZF/RARa	NULL
POZ-PLZF/RARa	NULL
PLZF/RARa	NULL
POZ-PLZF/RARa	NULL
I	NULL
42	NULL
i	NULL
B35	NULL
B47	NULL
|	NULL
I	NULL
B412	NULL
I	NULL
B49	NULL
B411	NULL
Zn	NULL
--	NULL
-	NULL
``	NULL
--	NULL
I	NULL
2	NULL
]	NULL
--	NULL
-I	NULL
``	NULL
-IT	NULL
O21	NULL
200	NULL
LLB——	NULL
w	NULL
tprovey	NULL
e	NULL
116	NULL
-	NULL
ge-	NULL
=_	NULL
g	NULL
PLZF/RAR	NULL
Ir	NULL
-	NULL
97	NULL
-	NULL
e	NULL
POZ-PLZF/RARa	NULL
66	NULL
-	NULL
66	NULL
a-RARa	NULL
a-PLZF	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
expression	NULL
of	NULL
PLZF-RARa	NULL
and	NULL
PML-RARa	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
POZ-PLZF-RARa	NULL
(	NULL
C	NULL
)	NULL
in	NULL
U937	NULL
,	NULL
HL-60	NULL
,	NULL
and	NULL
HL-60R	NULL
cells	NULL
.	NULL

The	NULL
proteins	NULL
,	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
clones	NULL
are	NULL
indicated	NULL
above	NULL
the	NULL
blots	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
(	NULL
in	NULL
thousands	NULL
)	NULL
are	NULL
given	NULL
to	NULL
the	NULL
left	NULL
of	NULL
each	NULL
blot	NULL
.	NULL

Each	NULL
lane	NULL
was	NULL
loaded	NULL
with	NULL
lysates	NULL
from	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
Zn	NULL
induction	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
empty	NULL
pMT	NULL
expression	NULL
vector	NULL
(	NULL
MT	NULL
)	NULL
.	NULL

The	NULL
Western	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
anti-RARa	NULL
(	NULL
aRARa	NULL
)	NULL
or	NULL
anti-PLZF	NULL
antibodies	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

4862	NULL
RUTHARDT	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

16	NULL
100	NULL
10	NULL
°M	NULL
RA	NULL
A	NULL
20	NULL
PRQ9	NULL
+	NULL
Zn	NULL
so	NULL
|	NULL
/	NULL
’	NULL
\	NULL
Ee	NULL
®	NULL
o	NULL
o	NULL
/	NULL
Control	NULL
PLZF/RARa	NULL
PML/RARa	NULL
3	NULL
60	NULL
/	NULL
®	NULL
B41	NULL
B42	NULL
B45	NULL
B412	NULL
PRS	NULL
3	NULL
50	NULL
}	NULL
120	NULL
E	NULL
ad	NULL
Z	NULL
119	NULL
S	NULL
so	NULL
/	NULL
PRY	NULL
c	NULL
xe	NULL
_-	NULL
$	NULL
2	NULL
``	NULL
°	NULL
20	NULL
zB	NULL
Bllizn	NULL
a	NULL
&	NULL
esa	NULL
--	NULL
--	NULL
-	NULL
Baz	NULL
5g	NULL
``	NULL
|	NULL
10	NULL
Z	NULL
_	NULL
-_	NULL
--	NULL
*~~	NULL
~	NULL
B412	NULL
+Zn	NULL
§§	NULL
so	NULL
|	NULL
o	NULL
HC	NULL
0	NULL
4	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
8	NULL
c	NULL
|	NULL
ays	NULL
ip	NULL
s	NULL
c	NULL
.	NULL

$	NULL
8	NULL
4	NULL
|	NULL
100	NULL
10	NULL
°M	NULL
RA	NULL
E	NULL
5	NULL
30	NULL
I	NULL
90	NULL
*	NULL
20	NULL
_7§	NULL
80	NULL
//k\	NULL
'	NULL
PR9	NULL
+	NULL
Zn	NULL
10	NULL
|	NULL
&	NULL
70	NULL
////	NULL
a	NULL
Tag	NULL
oun	NULL
nan	NULL
ram	NULL
es	NULL
&	NULL
60	NULL
//	NULL
C	NULL
hel	NULL
a.	NULL
gwéé	NULL
s	NULL
”	NULL
é	NULL
saw	NULL
?	NULL

gamer	NULL
;	NULL
Prwgg	NULL
E	NULL
50	NULL
/	NULL
TELL	NULL
®	NULL
par	NULL
upg	NULL
wow-	NULL
*	NULL
--	NULL
B49+Zn	NULL
Seses®	NULL
Sse	NULL
``	NULL
Sees	NULL
``	NULL
BSSSts	NULL
§	NULL
49	NULL
s	NULL
x	NULL
®	NULL
39	NULL
/	NULL
///	NULL
;	NULL
///	NULL
Pro	NULL
20	NULL
/	NULL
//	NULL
’	NULL
ao	NULL
10	NULL
}	NULL
=/	NULL
{	NULL
.r	NULL
msi	NULL
g	NULL
E	NULL
f/é	NULL
’	NULL
Co	NULL
-_	NULL
aii	NULL
4f	NULL
>	NULL
+zn	NULL
0	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
days	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Differentiation	NULL
levels	NULL
induced	NULL
by	NULL
D3-TGF	NULL
(	NULL
A	NULL
)	NULL
or	NULL
RA	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
in	NULL
U937	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
MT	NULL
vector	NULL
(	NULL
control	NULL
B41	NULL
clone	NULL
)	NULL
or	NULL
overexpressing	NULL
PLZF-RARa	NULL
(	NULL
B412	NULL
clone	NULL
)	NULL
,	NULL
PML-RARa	NULL
(	NULL
PR9	NULL
clone	NULL
)	NULL
,	NULL
or	NULL
POZ-PLZF-RARa	NULL
(	NULL
B49	NULL
clone	NULL
)	NULL
proteins	NULL
.	NULL

(	NULL
A	NULL
)	NULL
D3-TGF-induced	NULL
differentiation	NULL
was	NULL
measured	NULL
by	NULL
quantitative	NULL
expression	NULL
of	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
CD18	NULL
antigens	NULL
and	NULL
by	NULL
the	NULL
percentages	NULL
of	NULL
cells	NULL
with	NULL
phagocytic	NULL
activity	NULL
and	NULL
capacity	NULL
to	NULL
bind	NULL
LPS	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Zn	NULL
treatment	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
after	NULL
zinc-induced	NULL
expression	NULL
of	NULL
the	NULL
exogenous	NULL
proteins	NULL
are	NULL
expressed	NULL
as	NULL
percentages	NULL
of	NULL
the	NULL
values	NULL
obtained	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
zinc	NULL
.	NULL

Three	NULL
experiments	NULL
for	NULL
each	NULL
clone	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
standard	NULL
deviations	NULL
are	NULL
given	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
RA-induced	NULL
differentiation	NULL
was	NULL
measured	NULL
by	NULL
the	NULL
NBT	NULL
reduction	NULL
test	NULL
.	NULL

Each	NULL
experiment	NULL
is	NULL
representative	NULL
of	NULL
three	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

Terminal	NULL
differentiation	NULL
was	NULL
induced	NULL
by	NULL
4	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
D3-TGF	NULL
(	NULL
U937	NULL
and	NULL
HL-60	NULL
cells	NULL
)	NULL
or	NULL
DMSO	NULL
(	NULL
HL-60	NULL
cells	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Zn	NULL
and	NULL
monitored	NULL
by	NULL
quantitative	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
of	NULL
appropriate	NULL
surface	NULL
differentiation	NULL
antigens	NULL
(	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
CD14	NULL
,	NULL
CD18	NULL
,	NULL
phagocytic	NULL
activity	NULL
,	NULL
and	NULL
lipopolysaccharide	NULL
[	NULL
LPS	NULL
]	NULL
binding	NULL
in	NULL
U937	NULL
cells	NULL
treated	NULL
with	NULL
D3-TGF	NULL
;	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
CD14	NULL
,	NULL
CD18	NULL
,	NULL
and	NULL
CD54	NULL
in	NULL
HL60	NULL
cells	NULL
treated	NULL
with	NULL
D3-TGF	NULL
;	NULL
and	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
in	NULL
HL60	NULL
cells	NULL
treated	NULL
with	NULL
DMSO	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
all	NULL
of	NULL
these	NULL
markers	NULL
was	NULL
low	NULL
or	NULL
absent	NULL
in	NULL
the	NULL
unstimulated	NULL
parental	NULL
cell	NULL
lines	NULL
or	NULL
in	NULL
the	NULL
non-Zn-treated	NULL
clones	NULL
and	NULL
increased	NULL
progressively	NULL
during	NULL
differentiation	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
14	NULL
,	NULL
17	NULL
,	NULL
48	NULL
)	NULL
.	NULL

To	NULL
avoid	NULL
biases	NULL
of	NULL
clonality	NULL
and	NULL
culture	NULL
condition	NULL
variations	NULL
,	NULL
differentiation	NULL
was	NULL
evaluated	NULL
for	NULL
each	NULL
clone	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
Zn-induced	NULL
protein	NULL
expression	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
differentiation	NULL
marker	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Zn	NULL
with	NULL
respect	NULL
to	NULL
expression	NULL
in	NULL
its	NULL
absence	NULL
.	NULL

The	NULL
differentiation-related	NULL
increase	NULL
in	NULL
differentiation	NULL
marker	NULL
expression	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
Zn	NULL
treatment	NULL
in	NULL
either	NULL
HL-60	NULL
or	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
control	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
the	NULL
monocytic	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
induced	NULL
by	NULL
D3-TGF	NULL
are	NULL
reported	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
.	NULL

Both	NULL
the	NULL
B45	NULL
and	NULL
B412	NULL
PLZF-RARa-expressing	NULL
clones	NULL
differentiated	NULL
poorly	NULL
in	NULL
response	NULL
to	NULL
D3-TGF	NULL
after	NULL
Zn-induced	NULL
PLZF-RARa	NULL
expression	NULL
.	NULL

The	NULL
differentiative	NULL
block	NULL
mediated	NULL
by	NULL
PLZF-RARa	NULL
was	NULL
equal	NULL
(	NULL
CD14	NULL
antigen	NULL
,	NULL
phagocytic	NULL
activity	NULL
,	NULL
and	NULL
LPS	NULL
binding	NULL
)	NULL
or	NULL
superior	NULL
(	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
antigens	NULL
)	NULL
to	NULL
that	NULL
obtained	NULL
by	NULL
expressing	NULL
PML-RARa	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
clone	NULL
PR9	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
PLZF-RARa	NULL
«	NULL
expression	NULL
on	NULL
D3-TGF-induced	NULL
monocytic	NULL
and	NULL
DMSO-induced	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Zn-induced	NULL
PLZF-RARa	NULL
expression	NULL
impaired	NULL
the	NULL
capacity	NULL
of	NULL
the	NULL
B28	NULL
and	NULL
B211	NULL
clones	NULL
to	NULL
undergo	NULL
D3-TGF-	NULL
or	NULL
DMSO-induced	NULL
differentiation	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
differentiation	NULL
antigen	NULL
analysis	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
morphological	NULL
monitoring	NULL
of	NULL
differentiation	NULL
:	NULL
D3-TGF-	NULL
or	NULL
DMSO-treated	NULL
B28	NULL
and	NULL
B211	NULL
cells	NULL
maintained	NULL
their	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
Control	NULL
B31	NULL
B32	NULL
120	NULL
110	NULL
100	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
after	NULL
Zn	NULL
induction	NULL
in	NULL
respect	NULL
to	NULL
non	NULL
induced	NULL
cells	NULL
I	NULL
O	NULL
EFFECTS	NULL
OF	NULL
AND	NULL
PLZF-RAR	NULL
«	NULL
ON	NULL
RA	NULL
DIFFERENTIATION	NULL
_	NULL
4863	NULL
PLZF/RARa	NULL
B28	NULL
B211	NULL
5	NULL
3	NULL
20	NULL
10	NULL
Che	NULL
foe	NULL
Che	NULL
Cto	NULL
-	NULL
Che	NULL
che	NULL
Cosey	NULL
Coe	NULL
``	NULL
om	NULL
ans	NULL
aan	NULL
mSh	NULL
Sbb	NULL
mhbh§	NULL
bbs	NULL
bab	NULL
-	NULL
babes	NULL
Sob	NULL
555	NULL
©OOo0UO	NULL
OOO	NULL
OCU	NULL
OOO	NULL
OOO	NULL
OOO	NULL
COOOO	NULL
GOO	NULL
OOO	NULL
COOUOU	NULL
Oo	NULL
OCO	NULL
TGF/D3	NULL
-	NULL
DMSO	NULL
t-RA	NULL
TGF/ID3	NULL
-	NULL
DMSO	NULL
t-RA	NULL
TGF/ID3	NULL
-	NULL
DMSO	NULL
t-RA	NULL
TGF/ID3	NULL
-	NULL
DMSO	NULL
t-RA	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Differentiation	NULL
levels	NULL
induced	NULL
by	NULL
D3-TGF	NULL
,	NULL
DMSO	NULL
,	NULL
or	NULL
RA	NULL
in	NULL
HL-60	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
MT	NULL
vector	NULL
(	NULL
B31	NULL
and	NULL
B32	NULL
clones	NULL
)	NULL
or	NULL
overexpressing	NULL
PLZF-RARa	NULL
(	NULL
B28	NULL
and	NULL
B211	NULL
clones	NULL
)	NULL
.	NULL

Differentiation	NULL
was	NULL
measured	NULL
by	NULL
quantitative	NULL
expression	NULL
of	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
CD14	NULL
,	NULL
CD18	NULL
,	NULL
and	NULL
CD54	NULL
antigens	NULL
for	NULL
D3-TGF-treated	NULL
cells	NULL
and	NULL
of	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
antigens	NULL
for	NULL
DMSO-	NULL
and	NULL
RA-treated	NULL
cells	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Three	NULL
experiments	NULL
for	NULL
each	NULL
clone	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
standard	NULL
deviations	NULL
are	NULL
given	NULL
.	NULL

blast-like	NULL
morphology	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Zn-induced	NULL
PLZF-RARa	NULL
expression	NULL
,	NULL
while	NULL
they	NULL
acquired	NULL
typical	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
features	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Zn	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
PLZF-RARa	NULL
«	NULL
to	NULL
block	NULL
terminal	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
PML-RARa	NULL
because	NULL
HL-60	NULL
cells	NULL
are	NULL
not	NULL
permissive	NULL
for	NULL
PML-RARa	NULL
expression	NULL
(	NULL
14	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
PLZF-RARa	NULL
expression	NULL
blocks	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cell	NULL
lines	NULL
and	NULL
suggest	NULL
that	NULL
this	NULL
biological	NULL
activity	NULL
of	NULL
PLZF-RARa	NULL
,	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
PML-RAR	NULL
«	NULL
,	NULL
contributes	NULL
to	NULL
its	NULL
in	NULL
vivo	NULL
leukemogenetic	NULL
potential	NULL
.	NULL

PLZF-RARa	NULL
and	NULL
PML-RARa	NULL
«	NULL
have	NULL
different	NULL
effects	NULL
on	NULL
the	NULL
RA-induced	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
U937	NULL
and	NULL
HL-60	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
expression	NULL
of	NULL
PML-RARa	NULL
«	NULL
increases	NULL
the	NULL
sensitivity	NULL
of	NULL
U937	NULL
cells	NULL
to	NULL
the	NULL
differentiative	NULL
action	NULL
of	NULL
RA	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
RA-induced	NULL
differentiation	NULL
was	NULL
therefore	NULL
investigated	NULL
by	NULL
analyzing	NULL
the	NULL
RA	NULL
responses	NULL
of	NULL
U937	NULL
and	NULL
HL-60	NULL
cells	NULL
expressing	NULL
PLZF-RARa	NULL
.	NULL

U937	NULL
cells	NULL
differentiate	NULL
poorly	NULL
in	NULL
response	NULL
to	NULL
RA	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
percentage	NULL
of	NULL
differentiated	NULL
cells	NULL
(	NULL
between	NULL
20	NULL
and	NULL
50	NULL
%	NULL
)	NULL
and	NULL
the	NULL
degree	NULL
of	NULL
differentiation	NULL
(	NULL
no	NULL
modulation	NULL
of	NULL
the	NULL
conventional	NULL
differentiation	NULL
antigens	NULL
)	NULL
(	NULL
40	NULL
)	NULL
.	NULL

RA-induced	NULL
differentiation	NULL
of	NULL
U937	NULL
cells	NULL
is	NULL
usually	NULL
monitored	NULL
by	NULL
measuring	NULL
the	NULL
capacity	NULL
of	NULL
differentiated	NULL
cells	NULL
to	NULL
reduce	NULL
nitroblue	NULL
tetrazolium	NULL
(	NULL
NBT	NULL
)	NULL
.	NULL

The	NULL
B41	NULL
control	NULL
clone	NULL
differentiated	NULL
poorly	NULL
after	NULL
6	NULL
days	NULL
of	NULL
RA	NULL
treatment	NULL
,	NULL
and	NULL
differentiation	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
Zn	NULL
treatment	NULL
(	NULL
15	NULL
and	NULL
22	NULL
%	NULL
NBT-positive	NULL
cells	NULL
with	NULL
and	NULL
without	NULL
Zn	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
the	NULL
PML-RARa-transduced	NULL
cells	NULL
(	NULL
PR9	NULL
clone	NULL
)	NULL
,	NULL
RA	NULL
induced	NULL
a	NULL
comparable	NULL
low	NULL
degree	NULL
of	NULL
differentiation	NULL
when	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Zn	NULL
(	NULL
20	NULL
%	NULL
NBT	NULL
-positive	NULL
cells	NULL
)	NULL
,	NULL
while	NULL
differentiation	NULL
was	NULL
almost	NULL
complete	NULL
(	NULL
approximately	NULL
90	NULL
%	NULL
NBT	NULL
positivity	NULL
)	NULL
when	NULL
the	NULL
same	NULL
cells	NULL
were	NULL
induced	NULL
by	NULL
RA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Zn	NULL
.	NULL

The	NULL
response	NULL
to	NULL
RA	NULL
was	NULL
,	NULL
instead	NULL
,	NULL
modest	NULL
in	NULL
the	NULL
B412	NULL
PLZF-RARa-transfected	NULL
clone	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
Zn-induced	NULL
PLZF-RARa	NULL
expression	NULL
(	NULL
15	NULL
and	NULL
23	NULL
%	NULL
NBT	NULL
-positive	NULL
cells	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
using	NULL
another	NULL
PLZF-RARa	NULL
U937	NULL
clone	NULL
(	NULL
clone	NULL
B45	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
by	NULL
RA	NULL
can	NULL
be	NULL
monitored	NULL
by	NULL
analyzing	NULL
surface	NULL
differentiation	NULL
antigens	NULL
(	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
)	NULL
or	NULL
by	NULL
morphological	NULL
evaluation	NULL
.	NULL

PLZF-RARa	NULL
expression	NULL
blocked	NULL
RA-induced	NULL
differentiation	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
either	NULL
of	NULL
these	NULL
criteria	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
for	NULL
surface	NULL
marker	NULL
analysis	NULL
;	NULL
morphology	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
PLZF-RARa	NULL
«	NULL
expression	NULL
blocks	NULL
RA-induced	NULL
differentiation	NULL
.	NULL

The	NULL
effect	NULL
seems	NULL
to	NULL
differ	NULL
from	NULL
that	NULL
of	NULL
PML-RARa	NULL
,	NULL
which	NULL
,	NULL
at	NULL
least	NULL
in	NULL
the	NULL
U937	NULL
cells	NULL
,	NULL
increases	NULL
the	NULL
RA	NULL
response	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
exert	NULL
different	NULL
effects	NULL
on	NULL
the	NULL
RA	NULL
signalling	NULL
pathway	NULL
.	NULL

Direct	NULL
proof	NULL
for	NULL
this	NULL
proposal	NULL
was	NULL
searched	NULL
for	NULL
by	NULL
testing	NULL
the	NULL
capacities	NULL
of	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
to	NULL
restore	NULL
sensitivity	NULL
to	NULL
RA	NULL
in	NULL
RA-resistant	NULL
hematopoietic	NULL
cells	NULL
.	NULL

PML-RARa	NULL
,	NULL
but	NULL
not	NULL
PLZF-RARa	NULL
,	NULL
restores	NULL
the	NULL
sensitivity	NULL
to	NULL
RA	NULL
of	NULL
an	NULL
RA-resistant	NULL
HL-60	NULL
subline	NULL
.	NULL

HL-60R	NULL
is	NULL
an	NULL
HL-60	NULL
subline	NULL
selected	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
grow	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RA	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Resistance	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
4864	NULL
RUTHARDT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
O	NULL
066	NULL
C	NULL
xa	NULL
Uu	NULL
#	NULL
41	NULL
#	NULL
42	NULL
#	NULL
7	NULL
$	NULL
04	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

iV	NULL
-g	NULL
Au	NULL
|	NULL
Mu	NULL
08	NULL
U	NULL
#	NULL
10	NULL
#	NULL
121	NULL
#	NULL
13.1	NULL
B35	NULL
B47	NULL
#	NULL
34	NULL
#	NULL
43	NULL
100	NULL
90	NULL
80	NULL
70	NULL
60	NULL
50	NULL
40	NULL
30	NULL
20	NULL
10	NULL
%	NULL
of	NULL
positive	NULL
cells	NULL
Ca	NULL
ao	NULL
go	NULL
uo	NULL
-r0D	NULL
--	NULL
60	NULL
--	NULL
0	NULL
GQ	NULL
(	NULL
G.Q	NULL
o	NULL
UQ	NULL
Lo	NULL
--	NULL
0O	NULL
-	NULL
«	NULL
00	NULL
-O	NULL
)	NULL
--	NULL
00	NULL
wow-	NULL
mem	NULL
mem	NULL
v	NULL
onn	NULL
non	NULL
onmn	NULL
OOO	NULL
COO	NULL
OOO	NULL
Oc	NULL
Coo	NULL
OCO	NULL
om	NULL
om	NULL
nmn	NULL
am	NULL
nnn	NULL
©oo	NULL
©00	NULL
O00	NULL
G00	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Differentiation	NULL
levels	NULL
induced	NULL
by	NULL
RA	NULL
in	NULL
HL-60R	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
MT	NULL
vector	NULL
(	NULL
clones	NULL
41	NULL
and	NULL
42	NULL
)	NULL
or	NULL
overexpressing	NULL
RARa	NULL
«	NULL
(	NULL
clones	NULL
7	NULL
and	NULL
10	NULL
)	NULL
,	NULL
PML-RARa	NULL
(	NULL
clones	NULL
12.1	NULL
and	NULL
13.1	NULL
)	NULL
,	NULL
PLZF-RARa	NULL
«	NULL
(	NULL
clones	NULL
34	NULL
and	NULL
43	NULL
)	NULL
,	NULL
or	NULL
POZ-PLZEF-RARa	NULL
(	NULL
clones	NULL
B35	NULL
and	NULL
B47	NULL
)	NULL
.	NULL

Differentiation	NULL
was	NULL
measured	NULL
by	NULL
quantitative	NULL
expression	NULL
of	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
antigens	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percentages	NULL
of	NULL
positive	NULL
cells	NULL
after	NULL
RA	NULL
treatment	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Zn	NULL
induction	NULL
.	NULL

Three	NULL
experiments	NULL
for	NULL
each	NULL
clone	NULL
were	NULL
performed	NULL
,	NULL
and	NULL
standard	NULL
deviations	NULL
are	NULL
given	NULL
.	NULL

RARa	NULL
ligand	NULL
binding	NULL
domain	NULL
that	NULL
introduces	NULL
a	NULL
frameshift	NULL
and	NULL
results	NULL
in	NULL
premature	NULL
termination	NULL
of	NULL
the	NULL
receptor	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Rein-troduction	NULL
of	NULL
wild-type	NULL
RARa	NULL
in	NULL
these	NULL
cells	NULL
restores	NULL
sensitivity	NULL
to	NULL
RA	NULL
(	NULL
8	NULL
)	NULL
.	NULL

PML-RAR	NULL
«	NULL
a	NULL
,	NULL
PLZF-RAR	NULL
«	NULL
,	NULL
and	NULL
RARa	NULL
(	NULL
as	NULL
a	NULL
con-trol	NULL
)	NULL
cDNAs	NULL
were	NULL
transfected	NULL
into	NULL
HL-60R	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
pGMTSVneo	NULL
expression	NULL
vector	NULL
.	NULL

Two	NULL
clones	NULL
that	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
exogenous	NULL
protein	NULL
expression	NULL
after	NULL
Zn	NULL
induction	NULL
were	NULL
selected	NULL
from	NULL
each	NULL
transfection	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1B	NULL
for	NULL
PLZF-RARa	NULL
and	NULL
PML-RARa	NULL
«	NULL
protein	NULL
expression	NULL
results	NULL
)	NULL
.	NULL

Two	NULL
clones	NULL
transfected	NULL
with	NULL
the	NULL
empty	NULL
expression	NULL
vector	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
(	NULL
clones	NULL
41	NULL
and	NULL
42	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
HL-6O0R	NULL
cells	NULL
,	NULL
like	NULL
the	NULL
parental	NULL
HL-60	NULL
cells	NULL
,	NULL
are	NULL
not	NULL
permissive	NULL
for	NULL
PML-RARa	NULL
«	NULL
expression	NULL
(	NULL
14	NULL
)	NULL
and	NULL
that	NULL
we	NULL
obtained	NULL
HL-60R	NULL
(	NULL
but	NULL
not	NULL
HL-60	NULL
)	NULL
PML-RARa-expressing	NULL
clones	NULL
by	NULL
the	NULL
concomitant	NULL
expression	NULL
of	NULL
bel-2	NULL
.	NULL

The	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
bel2	NULL
makes	NULL
HL-60R	NULL
cells	NULL
permissive	NULL
for	NULL
PML-RARa	NULL
expression	NULL
will	NULL
be	NULL
reported	NULL
elsewhere	NULL
.	NULL

Parallel	NULL
control	NULL
experiments	NULL
revealed	NULL
that	NULL
bel2	NULL
expression	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
RA	NULL
sensitivity	NULL
of	NULL
HL-60R	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

RA	NULL
treatment	NULL
of	NULL
HL-60R	NULL
control	NULL
clones	NULL
neither	NULL
modified	NULL
their	NULL
growth	NULL
potential	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
nor	NULL
induced	NULL
differentiation	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
surface	NULL
marker	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
HL-6O0R	NULL
clones	NULL
41	NULL
and	NULL
42	NULL
)	NULL
and	NULL
morphological	NULL
analysis	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

RARa	NULL
expression	NULL
restored	NULL
RA	NULL
sensitivity	NULL
of	NULL
HL-6OR	NULL
cells	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
facts	NULL
that	NULL
cells	NULL
stopped	NULL
growing	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
acquired	NULL
the	NULL
ability	NULL
to	NULL
fully	NULL
express	NULL
differentiation	NULL
markers	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
clones	NULL
7	NULL
and	NULL
10	NULL
)	NULL
and	NULL
the	NULL
morphological	NULL
features	NULL
of	NULL
differentiated	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
when	NULL
treated	NULL
with	NULL
RA	NULL
.	NULL

Likewise	NULL
,	NULL
expression	NULL
of	NULL
PML-RARa	NULL
largely	NULL
restored	NULL
RA	NULL
sensitivity	NULL
of	NULL
HL-60R	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
clones	NULL
12.1	NULL
and	NULL
13.1	NULL
)	NULL
,	NULL
whereas	NULL
PLZF-RARa	NULL
«	NULL
did	NULL
not	NULL
,	NULL
except	NULL
for	NULL
a	NULL
mild	NULL
stimulatory	NULL
effect	NULL
on	NULL
CD18	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
clones	NULL
34	NULL
and	NULL
43	NULL
)	NULL
.	NULL

PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
«	NULL
have	NULL
similar	NULL
RA	NULL
binding	NULL
affinities	NULL
and	NULL
opposite	NULL
effects	NULL
on	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
vivo	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
mechanisms	NULL
underlying	NULL
the	NULL
opposite	NULL
effects	NULL
of	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
on	NULL
RA-mediated	NULL
differentiation	NULL
,	NULL
we	NULL
evaluated	NULL
their	NULL
capacities	NULL
to	NULL
bind	NULL
RA	NULL
and	NULL
to	NULL
activate	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
vivo	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
either	NULL
COS-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
PLZF-RARa	NULL
«	NULL
or	NULL
U937	NULL
B45	NULL
clone	NULL
stably	NULL
expressing	NULL
PLZF-RARa	NULL
were	NULL
labelled	NULL
for	NULL
18	NULL
h	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
[	NULL
°HJt-RA	NULL
and	NULL
analyzed	NULL
by	NULL
using	NULL
PD10	NULL
desalting	NULL
columns	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
affinity	NULL
of	NULL
t-RA	NULL
to	NULL
PLZF-RARa	NULL
was	NULL
analyzed	NULL
directly	NULL
by	NULL
saturation	NULL
ki-netics	NULL
and	NULL
Scatchard	NULL
analysis	NULL
and	NULL
compared	NULL
to	NULL
those	NULL
for	NULL
PMLRARa	NULL
and	NULL
RARa	NULL
(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
t-RA	NULL
binding	NULL
to	NULL
PLZF-RARa	NULL
was	NULL
specific	NULL
and	NULL
saturable	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Scatchard	NULL
analysis	NULL
of	NULL
this	NULL
binding	NULL
indicated	NULL
a	NULL
single	NULL
high-affinity	NULL
binding	NULL
site	NULL
on	NULL
PLZF-RARa	NULL
expressed	NULL
by	NULL
either	NULL
COS-1	NULL
or	NULL
U937	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
calculated	NULL
dissociation	NULL
constants	NULL
were	NULL
0.17	NULL
and	NULL
0.19	NULL
nM	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
determined	NULL
for	NULL
RARa	NULL
and	NULL
PML-RARa	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

U937	NULL
cells	NULL
expressing	NULL
PML-RARa	NULL
or	NULL
PLZF-RARa	NULL
«	NULL
were	NULL
then	NULL
analyzed	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
RA	NULL
on	NULL
four	NULL
RA	NULL
target	NULL
genes	NULL
(	NULL
those	NULL
for	NULL
RARB	NULL
,	NULL
RARy	NULL
,	NULL
CRABP1	NULL
,	NULL
and	NULL
CRABP2	NULL
)	NULL
(	NULL
25	NULL
,	NULL
35	NULL
,	NULL
38	NULL
,	NULL
47	NULL
)	NULL
and	NULL
on	NULL
the	NULL
type	NULL
II	NULL
TGase	NULL
gene	NULL
,	NULL
a	NULL
gene	NULL
that	NULL
is	NULL
regulated	NULL
by	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
TABLE	NULL
1	NULL
.	NULL

Dissociation	NULL
constants	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
t-RA	NULL
to	NULL
human	NULL
RARa	NULL
,	NULL
PML-RARa	NULL
,	NULL
or	NULL
PLZF-RARa	NULL
Transfected	NULL
RA-binding	NULL
Dissociation	NULL
cell	NULL
line	NULL
protein	NULL
constant	NULL
(	NULL
nM	NULL
)	NULL
*	NULL
CoS-1	NULL
RARa	NULL
0.09	NULL
+	NULL
0.03	NULL
PML-RARa	NULL
0.13	NULL
+	NULL
0.02	NULL
PLZF-RARa	NULL
0.17	NULL
+	NULL
0.01	NULL
U937	NULL
PLZF-RARa	NULL
0.19	NULL
+	NULL
0.06	NULL
*	NULL
Dissociation	NULL
constants	NULL
were	NULL
determined	NULL
by	NULL
Scatchard	NULL
analysis	NULL
.	NULL

Numbers	NULL
represents	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
for	NULL
at	NULL
least	NULL
three	NULL
individual	NULL
experi-ments	NULL
.	NULL

retinoids	NULL
and	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
marker	NULL
of	NULL
RA-induced	NULL
differentiation	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Type	NULL
II	NULL
TGase	NULL
was	NULL
assessed	NULL
by	NULL
measuring	NULL
cytosolic	NULL
TGase	NULL
activity	NULL
in	NULL
U937	NULL
control	NULL
cells	NULL
(	NULL
clone	NULL
B41	NULL
)	NULL
and	NULL
in	NULL
PML-RARa	NULL
(	NULL
clone	NULL
PR9	NULL
)	NULL
-	NULL
and	NULL
PLZF-RARa	NULL
(	NULL
clone	NULL
B412	NULL
)	NULL
-expressing	NULL
cells	NULL
before	NULL
RA	NULL
treatment	NULL
and	NULL
after	NULL
24	NULL
and	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
RA	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

A	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
of	NULL
TGase	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
B41	NULL
control	NULL
cells	NULL
after	NULL
48	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
,	NULL
irrespective	NULL
of	NULL
Zn	NULL
treatment	NULL
.	NULL

In	NULL
PR9	NULL
cells	NULL
induced	NULL
to	NULL
express	NULL
PML-RARa	NULL
,	NULL
TGase	NULL
activity	NULL
was	NULL
strongly	NULL
up-regulated	NULL
after	NULL
24	NULL
and	NULL
48	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
(	NULL
5-	NULL
to	NULL
10-fold	NULL
increase	NULL
over	NULL
that	NULL
in	NULL
non-Zn-induced	NULL
cells	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
PLZF-RARa-expressing	NULL
cells	NULL
there	NULL
was	NULL
no	NULL
induction	NULL
after	NULL
24	NULL
h	NULL
and	NULL
a	NULL
slight	NULL
down-regulation	NULL
of	NULL
TGase	NULL
activity	NULL
after	NULL
48	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

RARy	NULL
expression	NULL
was	NULL
evaluated	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
``	NULL
mRNA	NULL
from	NULL
U937	NULL
control	NULL
cells	NULL
(	NULL
clone	NULL
B41	NULL
)	NULL
or	NULL
cells	NULL
expressing	NULL
PML-RARa	NULL
(	NULL
clone	NULL
PR9	NULL
)	NULL
or	NULL
PLZF-RARa	NULL
«	NULL
(	NULL
clone	NULL
B412	NULL
)	NULL
,	NULL
with	NULL
the	NULL
full-length	NULL
RARy	NULL
cDNA	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

The	NULL
results	NULL
revealed	NULL
a	NULL
slight	NULL
up-regulation	NULL
of	NULL
the	NULL
RARy	NULL
transcript	NULL
in	NULL
the	NULL
control	NULL
B41	NULL
cells	NULL
after	NULL
24	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
and	NULL
disappearance	NULL
of	NULL
the	NULL
signal	NULL
after	NULL
48	NULL
h.	NULL
Instead	NULL
,	NULL
a	NULL
strong	NULL
induction	NULL
of	NULL
RARy	NULL
expression	NULL
was	NULL
detected	NULL
in	NULL
PML-RARa-expressing	NULL
cells	NULL
after	NULL
24	NULL
h	NULL
,	NULL
with	NULL
a	NULL
decline	NULL
in	NULL
the	NULL
hybridization	NULL
signal	NULL
after	NULL
48	NULL
h.	NULL
There	NULL
was	NULL
no	NULL
,	NULL
or	NULL
very	NULL
little	NULL
,	NULL
RARy	NULL
expression	NULL
in	NULL
PLZF-RARa-expressing	NULL
cells	NULL
after	NULL
either	NULL
24	NULL
or	NULL
48	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
approximately	NULL
3.5-kb	NULL
RARy-hybridizing	NULL
transcript	NULL
in	NULL
the	NULL
RNA	NULL
samples	NULL
from	NULL
PLZF-RARa-expressing	NULL
cells	NULL
derives	NULL
from	NULL
the	NULL
cross-hybridization	NULL
of	NULL
the	NULL
RARy	NULL
probe	NULL
with	NULL
the	NULL
PLZF-RARa	NULL
transcript	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
hybridization	NULL
of	NULL
the	NULL
same	NULL
blot	NULL
with	NULL
an	NULL
RARa	NULL
cDNA	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
from	NULL
the	NULL
same	NULL
U937	NULL
clones	NULL
was	NULL
also	NULL
analyzed	NULL
for	NULL
RARBG	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Since	NULL
we	NULL
have	NULL
noted	NULL
a	NULL
great	NULL
variability	NULL
in	NULL
the	NULL
degree	NULL
of	NULL
RARB	NULL
expression	NULL
after	NULL
RA	NULL
treatment	NULL
of	NULL
different	NULL
U937	NULL
clones	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
to	NULL
avoid	NULL
biases	NULL
from	NULL
clonal	NULL
variability	NULL
,	NULL
the	NULL
RARf	NULL
response	NULL
to	NULL
RA	NULL
was	NULL
compared	NULL
for	NULL
the	NULL
same	NULL
clones	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Zn	NULL
induction	NULL
.	NULL

Expression	NULL
of	NULL
PML-RARa	NULL
resulted	NULL
in	NULL
increased	NULL
accumulation	NULL
of	NULL
RARL	NULL
transcripts	NULL
after	NULL
24	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
non-Zn-treated	NULL
cells	NULL
,	NULL
while	NULL
PLZF-RARa	NULL
expression	NULL
did	NULL
not	NULL
affect	NULL
RARBG	NULL
expression	NULL
at	NULL
the	NULL
same	NULL
time	NULL
point	NULL
after	NULL
RA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

CRABP1	NULL
and	NULL
CRABP2	NULL
genes	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
U937	NULL
cells	NULL
under	NULL
any	NULL
culture	NULL
condition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
PML-RARa	NULL
«	NULL
potentiates	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
TGase	NULL
and	NULL
the	NULL
two	NULL
tested	NULL
RA	NULL
target	NULL
genes	NULL
(	NULL
RARB	NULL
and	NULL
RARy	NULL
)	NULL
,	NULL
while	NULL
PLZF-RARa	NULL
«	NULL
either	NULL
exerts	NULL
no	NULL
effect	NULL
on	NULL
(	NULL
RARB	NULL
)	NULL
or	NULL
inhibits	NULL
(	NULL
TGase	NULL
and	NULL
RARy	NULL
)	NULL
RA	NULL
target	NULL
gene	NULL
activation	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
POZ	NULL
domain	NULL
partially	NULL
releases	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
RA	NULL
signalling	NULL
.	NULL

The	NULL
PLZF-RARa	NULL
fusion	NULL
protein	NULL
retains	NULL
the	NULL
POZ	NULL
domain	NULL
of	NULL
PLZF	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
POZ	NULL
EFFECTS	NULL
OF	NULL
PML-RARe	NULL
AND	NULL
PLZF-RARa	NULL
«	NULL
ON	NULL
RA	NULL
DIFFERENTIATION	NULL
-	NULL
4865	NULL
domain	NULL
is	NULL
a	NULL
120-amino-acid	NULL
conserved	NULL
motif	NULL
present	NULL
in	NULL
a	NULL
large	NULL
family	NULL
of	NULL
proteins	NULL
that	NULL
includes	NULL
a	NULL
variety	NULL
of	NULL
zinc	NULL
finger	NULL
proteins	NULL
and	NULL
a	NULL
group	NULL
of	NULL
poxvirus	NULL
proteins	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
POZ	NULL
domains	NULL
from	NULL
the	NULL
zinc	NULL
finger	NULL
proteins	NULL
ZID	NULL
,	NULL
Ttk	NULL
,	NULL
and	NULL
GAGA	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
function	NULL
as	NULL
protein	NULL
interaction	NULL
domains	NULL
and	NULL
to	NULL
inhibit	NULL
the	NULL
interaction	NULL
of	NULL
their	NULL
associated	NULL
DNA	NULL
binding	NULL
regions	NULL
with	NULL
DNA	NULL
(	NULL
1	NULL
)	NULL
.	NULL

To	NULL
preliminarily	NULL
investigate	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
through	NULL
which	NULL
the	NULL
fusion	NULL
of	NULL
PLZF	NULL
with	NULL
RARa	NULL
«	NULL
results	NULL
in	NULL
a	NULL
protein	NULL
with	NULL
inhibitory	NULL
activity	NULL
on	NULL
the	NULL
RA-dependent	NULL
signalling	NULL
pathway	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
POZ	NULL
domain	NULL
on	NULL
the	NULL
capacity	NULL
of	NULL
PLZF-RARa	NULL
to	NULL
block	NULL
RA	NULL
differentiation	NULL
and	NULL
to	NULL
repress	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
PLZF-RARa	NULL
mutant	NULL
with	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
region	NULL
encoding	NULL
the	NULL
PLZF	NULL
POZ	NULL
domain	NULL
(	NULL
POZ-PLZF-RARa	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
was	NULL
cloned	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Zn-inducible	NULL
MT-1	NULL
promoter	NULL
and	NULL
electroporated	NULL
into	NULL
U937	NULL
and	NULL
HL-60R	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
POZ-PLZF-RARa	NULL
polypeptide	NULL
was	NULL
analyzed	NULL
in	NULL
individual	NULL
clones	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-PLZF	NULL
antibodies	NULL
.	NULL

Two	NULL
clones	NULL
each	NULL
of	NULL
U937	NULL
(	NULL
B49	NULL
and	NULL
B411	NULL
)	NULL
and	NULL
HL6OR	NULL
(	NULL
B35	NULL
and	NULL
B47	NULL
)	NULL
cells	NULL
were	NULL
chosen	NULL
for	NULL
further	NULL
analysis	NULL
based	NULL
on	NULL
their	NULL
levels	NULL
of	NULL
exogenous	NULL
protein	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Immunofluorescence	NULL
analysis	NULL
with	NULL
anti-PLZF	NULL
antibodies	NULL
revealed	NULL
that	NULL
the	NULL
POZ-PLZF-RARa	NULL
polypeptide	NULL
had	NULL
the	NULL
same	NULL
microsplecked	NULL
localization	NULL
as	NULL
PLZF-RARa	NULL
«	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
then	NULL
compared	NULL
the	NULL
capacities	NULL
of	NULL
U937	NULL
and	NULL
HLGOR	NULL
cells	NULL
expressing	NULL
POZ-PLZF-RAR	NULL
«	NULL
,	NULL
PLZF-RARa	NULL
,	NULL
or	NULL
PML-RARa	NULL
to	NULL
differentiate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RA	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
Zn	NULL
treatment	NULL
,	NULL
RA	NULL
induced	NULL
a	NULL
similarly	NULL
low	NULL
degree	NULL
of	NULL
differentiation	NULL
(	NULL
10	NULL
to	NULL
20	NULL
%	NULL
NBT	NULL
-positive	NULL
cells	NULL
)	NULL
of	NULL
U937	NULL
cells	NULL
expressing	NULL
POZ-PLZF-RARa	NULL
,	NULL
PLZF-RARa	NULL
,	NULL
or	NULL
PML-RARa	NULL
.	NULL

However	NULL
,	NULL
upon	NULL
Zn	NULL
induction	NULL
of	NULL
exogenous	NULL
protein	NULL
expression	NULL
,	NULL
RA-induced	NULL
differentiation	NULL
increased	NULL
to	NULL
approximately	NULL
40	NULL
to	NULL
50	NULL
%	NULL
in	NULL
the	NULL
POZ-PLZF-RARa	NULL
U937	NULL
cells	NULL
,	NULL
a	NULL
level	NULL
which	NULL
was	NULL
intermediate	NULL
between	NULL
those	NULL
of	NULL
PLZF-RARa	NULL
«	NULL
(	NULL
approximately	NULL
20	NULL
%	NULL
)	NULL
and	NULL
PML-RARa	NULL
«	NULL
(	NULL
approximately	NULL
90	NULL
%	NULL
)	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
HL6OR	NULL
cells	NULL
:	NULL
RA	NULL
treatment	NULL
of	NULL
POZ-PLZF-RARa-expressing	NULL
HL6OR	NULL
cells	NULL
induced	NULL
partial	NULL
up-regulation	NULL
of	NULL
the	NULL
CD11a	NULL
,	NULL
CD11b	NULL
,	NULL
and	NULL
CD18	NULL
differentiation	NULL
antigens	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

U937	NULL
cells	NULL
expressing	NULL
POZ-PLZF-RARa	NULL
were	NULL
then	NULL
analyzed	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
RA	NULL
on	NULL
TGase	NULL
and	NULL
RARy	NULL
.	NULL

In	NULL
PR9	NULL
cells	NULL
induced	NULL
to	NULL
express	NULL
POZ-PLZF-RARa	NULL
,	NULL
TGase	NULL
activity	NULL
was	NULL
up-regulated	NULL
after	NULL
24	NULL
and	NULL
48	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
(	NULL
three-	NULL
to	NULL
fourfold	NULL
increase	NULL
over	NULL
that	NULL
in	NULL
non-Zn-induced	NULL
cells	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
there	NULL
was	NULL
no	NULL
,	NULL
or	NULL
very	NULL
little	NULL
,	NULL
RARy	NULL
expression	NULL
in	NULL
POZ-PLZF-RARa-expressing	NULL
cells	NULL
after	NULL
either	NULL
24	NULL
or	NULL
48	NULL
h	NULL
of	NULL
RA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
sensitivity	NULL
of	NULL
U937	NULL
and	NULL
HL6GOR	NULL
cells	NULL
expressing	NULL
POZ-PLZF-RARa	NULL
to	NULL
the	NULL
differentiative	NULL
action	NULL
of	NULL
RA	NULL
revealed	NULL
that	NULL
the	NULL
POZ-PLZF-RARa	NULL
mutant	NULL
is	NULL
able	NULL
to	NULL
mediate	NULL
RA	NULL
sensitivity	NULL
,	NULL
although	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
than	NULL
PML-RARa	NULL
,	NULL
therefore	NULL
suggesting	NULL
that	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
POZ	NULL
domain	NULL
partially	NULL
releases	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
PLZF-RARa	NULL
.	NULL

However	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
capacity	NULL
of	NULL
the	NULL
POZ-PLZF-RARa	NULL
protein	NULL
to	NULL
activate	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
vivo	NULL
yielded	NULL
heterogeneous	NULL
results	NULL
:	NULL
this	NULL
protein	NULL
potentiated	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
TGases	NULL
,	NULL
while	NULL
it	NULL
exerted	NULL
no	NULL
effect	NULL
on	NULL
RARy	NULL
gene	NULL
activation	NULL
.	NULL

DISCUSSION	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
are	NULL
the	NULL
abnormal	NULL
protein	NULL
products	NULL
of	NULL
APLs	NULL
with	NULL
either	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
or	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
.	NULL

These	NULL
two	NULL
APL	NULL
types	NULL
are	NULL
phenotypically	NULL
indistinguishable	NULL
,	NULL
from	NULL
the	NULL
point	NULL
of	NULL
view	NULL
of	NULL
both	NULL
the	NULL
morphology	NULL
of	NULL
the	NULL
leukemic	NULL
blasts	NULL
and	NULL
the	NULL
4866	NULL
RUTHARDT	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
Control	NULL
PLZF/RARa	NULL
POZ-PLZF/RARa	NULL
PML/RARa	NULL
B41	NULL
B412	NULL
B49	NULL
PR9	NULL
30	NULL
p	NULL
_	NULL
25	NULL
3	NULL
2	NULL
8	NULL
$	NULL
20	NULL
+	NULL
5	NULL
e	NULL
15	NULL
§E	NULL
10	NULL
o	NULL
5	NULL
|	NULL
0	NULL
RA	NULL
-__	NULL
LJL	NULL
Op	NULL
og	NULL
LL	NULL
ff	NULL
of	NULL
Eo	NULL
p	NULL
ff	NULL
f	NULL
EL	NULL
cL	NULL
cl	NULL
hr	NULL
0	NULL
_	NULL
24	NULL
48	NULL
0	NULL
_	NULL
24	NULL
48	NULL
0	NULL
_	NULL
24	NULL
48	NULL
0	NULL
_	NULL
24	NULL
48	NULL
B	NULL
Control	NULL
PLZF/RARa	NULL
PML/RARa	NULL
POZ-PLZF/RARa	NULL
I	NULL
I	NULL
--	NULL
i	NULL
LJ	NULL
1	NULL
Zn	NULL
-	NULL
4	NULL
4	NULL
4+	NULL
-	NULL
4+	NULL
4	NULL
4+	NULL
-	NULL
+o	NULL
4+	NULL
4+	NULL
-	NULL
4+	NULL
o	NULL
+o+	NULL
``	NULL
Ra	NULL
*	NULL
``	NULL
%	NULL
-	NULL
PLZF/RARa	NULL
RARY	NULL
P	NULL
f	NULL
3	NULL
-	NULL
RARy	NULL
GAPDH	NULL
ie	NULL
=e	NULL
»	NULL
e	NULL
«	NULL
Ceo	NULL
RA	NULL
L-__J	NULL
+	NULL
+	NULL
L_	NULL
J	NULL
+	NULL
+	NULL
Ls	NULL
+	NULL
+	NULL
Lz	NULL
l	NULL
+	NULL
+	NULL
hr	NULL
_	NULL
O0	NULL
24	NULL
48	NULL
0	NULL
2448	NULL
O0	NULL
2448	NULL
O	NULL
_	NULL
24	NULL
48	NULL
C	NULL
PLZF/RARa	NULL
-	NULL
PML/RARa	NULL
Zn	NULL
-o	NULL
t	NULL
-o	NULL
$	NULL
o	NULL
-	NULL
$	NULL
-	NULL
+	NULL
un	NULL
-_	NULL
«	NULL
#	NULL
-	NULL
we	NULL
GAPDH	NULL
@	NULL
«	NULL
«	NULL
Cegez	NULL
RA	NULL
L-	NULL
_-	NULL
JL	NULL
+	NULL
__+	NULL
)	NULL
JL	NULL
-	NULL
___	NULL
JL	NULL
+__+J	NULL
hr	NULL
0	NULL
24	NULL
_	NULL
0	NULL
24	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

RA-induced	NULL
modulation	NULL
of	NULL
type	NULL
II	NULL
TGase	NULL
activity	NULL
and	NULL
RARy	NULL
and	NULL
RARB	NULL
expression	NULL
in	NULL
control	NULL
U937	NULL
cells	NULL
(	NULL
B41	NULL
clone	NULL
)	NULL
and	NULL
U937	NULL
cells	NULL
expressing	NULL
PLZF-RARa	NULL
(	NULL
B412	NULL
clone	NULL
)	NULL
,	NULL
POZ-PLZF-RARa	NULL
(	NULL
B49	NULL
clone	NULL
)	NULL
,	NULL
or	NULL
PML-RARa	NULL
(	NULL
PR9	NULL
clone	NULL
)	NULL
.	NULL

The	NULL
various	NULL
cell	NULL
samples	NULL
were	NULL
analyzed	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
Zn	NULL
induction	NULL
before	NULL
(	NULL
time	NULL
zero	NULL
)	NULL
or	NULL
24	NULL
or	NULL
48	NULL
h	NULL
after	NULL
RA	NULL
(	NULL
+	NULL
)	NULL
or	NULL
ethanol	NULL
(	NULL
-	NULL
)	NULL
treatment	NULL
.	NULL

(	NULL
A	NULL
)	NULL
TGase	NULL
activity	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
for	NULL
triplicate	NULL
samples	NULL
from	NULL
a	NULL
single	NULL
experiment	NULL
.	NULL

This	NULL
experiment	NULL
is	NULL
representative	NULL
of	NULL
three	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Northern	NULL
blotting	NULL
analysis	NULL
of	NULL
RARy	NULL
(	NULL
B	NULL
)	NULL
and	NULL
RARBG	NULL
(	NULL
C	NULL
)	NULL
expression	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
mRNA	NULL
(	NULL
B	NULL
)	NULL
or	NULL
total	NULL
mRNA	NULL
(	NULL
C	NULL
)	NULL
from	NULL
the	NULL
indicated	NULL
samples	NULL
was	NULL
hybridized	NULL
with	NULL
an	NULL
RARy	NULL
(	NULL
B	NULL
)	NULL
or	NULL
(	NULL
C	NULL
)	NULL
cDNA	NULL
probe	NULL
.	NULL

The	NULL
same	NULL
filters	NULL
were	NULL
hybridized	NULL
with	NULL
a	NULL
GAPDH	NULL
cDNA	NULL
probe	NULL
.	NULL

clinical	NULL
presentation	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Therapeutically	NULL
,	NULL
however	NULL
,	NULL
they	NULL
differ	NULL
in	NULL
that	NULL
the	NULL
type	NULL
that	NULL
expresses	NULL
PML-RARa	NULL
«	NULL
responds	NULL
to	NULL
RA	NULL
treatment	NULL
,	NULL
whereas	NULL
the	NULL
type	NULL
that	NULL
expresses	NULL
PLZF-RARa	NULL
does	NULL
not	NULL
(	NULL
15	NULL
,	NULL
50	NULL
,	NULL
51	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
pharmacological	NULL
doses	NULL
of	NULL
RA	NULL
,	NULL
the	NULL
biolog-	NULL
ical	NULL
activity	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
the	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursors	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
PML-RARa	NULL
.	NULL

PLZF-RARa	NULL
blocks	NULL
D3-induced	NULL
monocytic	NULL
differentiation	NULL
to	NULL
the	NULL
same	NULL
extent	NULL
as	NULL
PML-RARa	NULL
.	NULL

PLZF-RARa	NULL
was	NULL
also	NULL
demonstrated	NULL
to	NULL
block	NULL
DMSO	NULL
-stimulated	NULL
granulocytic	NULL
differentia-	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
tion	NULL
in	NULL
the	NULL
myeloblastic	NULL
HL-60	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
found	NULL
that	NULL
PLZF-RARa	NULL
blocks	NULL
the	NULL
granulocyte	NULL
colony-stimu-lating	NULL
factor-induced	NULL
granulocytic-erythroid	NULL
differentiation	NULL
of	NULL
the	NULL
multipotent	NULL
32-D	NULL
cell	NULL
line	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

No	NULL
such	NULL
information	NULL
is	NULL
available	NULL
for	NULL
the	NULL
PML-RARa	NULL
fusion	NULL
protein	NULL
,	NULL
as	NULL
its	NULL
expression	NULL
induces	NULL
death	NULL
of	NULL
HL-60	NULL
,	NULL
32-D	NULL
,	NULL
and	NULL
other	NULL
precursor	NULL
cell	NULL
lines	NULL
(	NULL
11a	NULL
)	NULL
.	NULL

It	NULL
therefore	NULL
appears	NULL
that	NULL
PLZF-RARa	NULL
is	NULL
able	NULL
to	NULL
block	NULL
multilineage	NULL
myeloid	NULL
differentiation	NULL
triggered	NULL
by	NULL
different	NULL
agents	NULL
(	NULL
D3-TGF	NULL
,	NULL
DMSO	NULL
,	NULL
and	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
)	NULL
with	NULL
seemingly	NULL
different	NULL
mechanisms	NULL
of	NULL
ac-tion	NULL
.	NULL

When	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
two	NULL
fusion	NULL
proteins	NULL
on	NULL
the	NULL
RA	NULL
differentiative	NULL
response	NULL
are	NULL
examined	NULL
,	NULL
PLZF-RARa	NULL
«	NULL
and	NULL
PML-RARa	NULL
are	NULL
found	NULL
to	NULL
behave	NULL
differently	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
PML-RARa	NULL
enhances	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
cells	NULL
that	NULL
respond	NULL
poorly	NULL
to	NULL
RA	NULL
(	NULL
U937	NULL
cells	NULL
)	NULL
(	NULL
14	NULL
)	NULL
.	NULL

We	NULL
now	NULL
extend	NULL
this	NULL
observation	NULL
to	NULL
RA-resistant	NULL
cells	NULL
and	NULL
show	NULL
that	NULL
PML-RARa	NULL
is	NULL
also	NULL
able	NULL
to	NULL
confer	NULL
sensitivity	NULL
to	NULL
RA	NULL
to	NULL
these	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PLZF-RARa	NULL
«	NULL
is	NULL
not	NULL
able	NULL
to	NULL
do	NULL
so	NULL
in	NULL
RA-resistant	NULL
cells	NULL
,	NULL
and	NULL
it	NULL
inhibits	NULL
the	NULL
RA	NULL
response	NULL
of	NULL
both	NULL
poorly	NULL
(	NULL
U937	NULL
)	NULL
and	NULL
highly	NULL
(	NULL
HL-60	NULL
)	NULL
responsive	NULL
cells	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
promyelocytic	NULL
blasts	NULL
to	NULL
the	NULL
action	NULL
of	NULL
RA	NULL
therefore	NULL
seems	NULL
to	NULL
strictly	NULL
depend	NULL
on	NULL
the	NULL
type	NULL
of	NULL
fusion	NULL
protein	NULL
present	NULL
.	NULL

Even	NULL
though	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
on	NULL
the	NULL
cell	NULL
response	NULL
to	NULL
RA	NULL
are	NULL
different	NULL
,	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
both	NULL
fusion	NULL
proteins	NULL
retain	NULL
the	NULL
same	NULL
portion	NULL
of	NULL
RARa	NULL
,	NULL
from	NULL
the	NULL
B	NULL
to	NULL
the	NULL
F	NULL
domain	NULL
(	NULL
5	NULL
,	NULL
43	NULL
)	NULL
.	NULL

A	NULL
convincing	NULL
hypothesis	NULL
would	NULL
be	NULL
that	NULL
the	NULL
response	NULL
of	NULL
promyelocytic	NULL
blasts	NULL
to	NULL
the	NULL
action	NULL
of	NULL
RA	NULL
is	NULL
the	NULL
direct	NULL
consequence	NULL
of	NULL
PML-RARa	NULL
or	NULL
PLZF-RARa	NULL
«	NULL
activity	NULL
on	NULL
the	NULL
RA	NULL
signalling	NULL
pathway	NULL
.	NULL

Our	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
proposal	NULL
that	NULL
pharmacological	NULL
doses	NULL
of	NULL
RA	NULL
induce	NULL
PML-RARa	NULL
,	NULL
but	NULL
not	NULL
PLZF-RARa	NULL
,	NULL
to	NULL
act	NULL
as	NULL
an	NULL
activator	NULL
on	NULL
RA-responsive	NULL
genes	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
response	NULL
to	NULL
RA	NULL
of	NULL
three	NULL
RA	NULL
target	NULL
genes	NULL
(	NULL
those	NULL
for	NULL
TGase	NULL
,	NULL
RARf	NULL
,	NULL
and	NULL
RARy	NULL
)	NULL
in	NULL
U937	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
PML-RARa	NULL
or	NULL
PLZF-RARa	NULL
and	NULL
found	NULL
that	NULL
the	NULL
response	NULL
was	NULL
enhanced	NULL
by	NULL
PML-RARa	NULL
but	NULL
was	NULL
unaffected	NULL
or	NULL
repressed	NULL
by	NULL
PLZF-RARa	NULL
.	NULL

It	NULL
is	NULL
somewhat	NULL
surprising	NULL
that	NULL
PLZF-RARa	NULL
and	NULL
PML-RARa	NULL
regulate	NULL
RA	NULL
target	NULL
genes	NULL
differently	NULL
in	NULL
vivo	NULL
,	NULL
seeing	NULL
that	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
have	NULL
analogous	NULL
transactivating	NULL
properties	NULL
on	NULL
cloned	NULL
RA-responsive	NULL
reporter	NULL
genes	NULL
in	NULL
transient-transfection	NULL
experiments	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Different	NULL
regulation	NULL
of	NULL
cloned	NULL
and	NULL
native	NULL
promoters	NULL
might	NULL
explain	NULL
this	NULL
discrepancy	NULL
.	NULL

The	NULL
mechanism	NULL
through	NULL
which	NULL
the	NULL
PML-RARa	NULL
«	NULL
fusion	NULL
results	NULL
in	NULL
a	NULL
protein	NULL
with	NULL
high	NULL
RA-dependent	NULL
enhancer	NULL
activity	NULL
on	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
vivo	NULL
,	NULL
while	NULL
the	NULL
PLZF-RARa	NULL
«	NULL
fusion	NULL
does	NULL
not	NULL
,	NULL
remains	NULL
unclear	NULL
.	NULL

The	NULL
distinct	NULL
transcriptional	NULL
properties	NULL
of	NULL
the	NULL
fusion	NULL
proteins	NULL
might	NULL
derive	NULL
from	NULL
their	NULL
different	NULL
abilities	NULL
to	NULL
bind	NULL
DNA	NULL
,	NULL
RA	NULL
,	NULL
or	NULL
a	NULL
variety	NULL
of	NULL
nuclear	NULL
factors	NULL
that	NULL
physiolog-ically	NULL
form	NULL
complexes	NULL
with	NULL
RARs	NULL
(	NULL
RXRs	NULL
,	NULL
corepressors	NULL
,	NULL
and	NULL
co-activators	NULL
)	NULL
(	NULL
36	NULL
)	NULL
.	NULL

RARs	NULL
are	NULL
ligand-dependent	NULL
transcription	NULL
factors	NULL
that	NULL
activate	NULL
transcription	NULL
through	NULL
specific	NULL
DNA	NULL
binding	NULL
sites	NULL
(	NULL
RA-responsive	NULL
elements	NULL
[	NULL
RAREs	NULL
]	NULL
)	NULL
in	NULL
their	NULL
target	NULL
genes	NULL
.	NULL

RARs	NULL
bind	NULL
RA	NULL
target	NULL
gene	NULL
promoters	NULL
in	NULL
physical	NULL
association	NULL
with	NULL
RXRs	NULL
,	NULL
a	NULL
family	NULL
of	NULL
retinoid	NULL
receptors	NULL
which	NULL
act	NULL
as	NULL
cofactors	NULL
for	NULL
several	NULL
other	NULL
nuclear	NULL
receptors	NULL
(	NULL
3	NULL
,	NULL
34	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
,	NULL
corepressors	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
RAR-RXR	NULL
heterodimer	NULL
,	NULL
thus	NULL
determining	NULL
transcriptional	NULL
repression	NULL
(	NULL
4	NULL
,	NULL
19	NULL
,	NULL
28	NULL
)	NULL
.	NULL

RA	NULL
:	NULL
RAR-RXR	NULL
interaction	NULL
induces	NULL
the	NULL
dissociation	NULL
of	NULL
the	NULL
corepressors	NULL
and	NULL
the	NULL
recruitment	NULL
of	NULL
coactivators	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
transcriptionally	NULL
active	NULL
complex	NULL
(	NULL
23	NULL
,	NULL
29	NULL
,	NULL
30	NULL
,	NULL
41	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Both	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
retain	NULL
most	NULL
of	NULL
the	NULL
RARa	NULL
protein	NULL
and	NULL
thus	NULL
the	NULL
potential	NULL
to	NULL
bind	NULL
DNA	NULL
,	NULL
RA	NULL
,	NULL
and	NULL
the	NULL
various	NULL
RAR-RXR	NULL
cofactors	NULL
.	NULL

Indeed	NULL
,	NULL
both	NULL
fusion	NULL
proteins	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
RAREs	NULL
,	NULL
to	NULL
transactivate	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
EFFECTS	NULL
OF	NULL
AND	NULL
PLZF-RAR	NULL
«	NULL
ON	NULL
RA	NULL
DIFFERENTIATION	NULL
_	NULL
4867	NULL
vitro	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
and	NULL
references	NULL
10	NULL
,	NULL
22	NULL
,	NULL
24	NULL
,	NULL
32	NULL
,	NULL
and	NULL
42	NULL
)	NULL
,	NULL
and	NULL
to	NULL
bind	NULL
RXRs	NULL
(	NULL
11	NULL
,	NULL
32	NULL
,	NULL
44	NULL
)	NULL
and	NULL
RA	NULL
(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
PLZF-RARa	NULL
to	NULL
distinct	NULL
RAREs	NULL
is	NULL
slightly	NULL
different	NULL
from	NULL
that	NULL
of	NULL
PML-RARa	NULL
,	NULL
thereby	NULL
suggesting	NULL
that	NULL
the	NULL
two	NULL
fusion	NULL
proteins	NULL
may	NULL
have	NULL
different	NULL
target	NULL
gene	NULL
specificities	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
PML-RARa	NULL
and	NULL
PLZF-RARa	NULL
«	NULL
to	NULL
bind	NULL
to	NULL
RAR-RXR	NULL
coactivators	NULL
and	NULL
corepressors	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
defined	NULL
.	NULL

However	NULL
,	NULL
since	NULL
these	NULL
interactions	NULL
were	NULL
mapped	NULL
to	NULL
RARa	NULL
regions	NULL
which	NULL
are	NULL
retained	NULL
within	NULL
both	NULL
fusion	NULL
proteins	NULL
(	NULL
the	NULL
RAR	NULL
hinge	NULL
region	NULL
and	NULL
AF-2	NULL
domain	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
they	NULL
are	NULL
unlikely	NULL
to	NULL
account	NULL
for	NULL
the	NULL
differences	NULL
between	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
.	NULL

Alternative	NULL
explanations	NULL
can	NULL
be	NULL
envisioned	NULL
.	NULL

The	NULL
different	NULL
regulation	NULL
of	NULL
RA	NULL
target	NULL
genes	NULL
by	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
might	NULL
result	NULL
from	NULL
differential	NULL
recruitment	NULL
of	NULL
nuclear	NULL
factors	NULL
through	NULL
the	NULL
PML	NULL
or	NULL
PLZF	NULL
moiety	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
.	NULL

They	NULL
both	NULL
contain	NULL
unique	NULL
protein-protein	NULL
dimerization	NULL
interfaces	NULL
:	NULL
the	NULL
PML	NULL
coiled-coil	NULL
region	NULL
,	NULL
which	NULL
contains	NULL
four	NULL
clusters	NULL
of	NULL
heptad	NULL
repeats	NULL
with	NULL
hydrophobic	NULL
amino	NULL
acids	NULL
at	NULL
the	NULL
first	NULL
,	NULL
fourth	NULL
,	NULL
and	NULL
eighth	NULL
positions	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
the	NULL
PLZF	NULL
POZ	NULL
domain	NULL
,	NULL
an	NULL
approximately	NULL
120-amino-acid	NULL
motif	NULL
which	NULL
characterizes	NULL
a	NULL
subfamily	NULL
of	NULL
C2-H2	NULL
zinc	NULL
finger	NULL
proteins	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
coiled-coil	NULL
region	NULL
and	NULL
the	NULL
POZ	NULL
domain	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PML-RARa	NULL
(	NULL
39	NULL
)	NULL
and	NULL
PLZF-RARa	NULL
(	NULL
our	NULL
unpublished	NULL
results	NULL
)	NULL
high-molecular-weight	NULL
nuclear	NULL
complexes	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
their	NULL
integrity	NULL
is	NULL
crucial	NULL
for	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
both	NULL
fusion	NULL
proteins	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
PML	NULL
coiled-coil	NULL
region	NULL
abrogates	NULL
the	NULL
capacity	NULL
of	NULL
PML-RARa	NULL
«	NULL
to	NULL
block	NULL
D3-induced	NULL
differentiation	NULL
and	NULL
to	NULL
increase	NULL
RA	NULL
sensitivity	NULL
(	NULL
17	NULL
)	NULL
,	NULL
while	NULL
deletion	NULL
of	NULL
the	NULL
POZ	NULL
domain	NULL
partially	NULL
releases	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
the	NULL
RA-induced	NULL
differentiation	NULL
and	NULL
RA-mediated	NULL
activation	NULL
of	NULL
TGase	NULL
.	NULL

While	NULL
the	NULL
proteins	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
PML	NULL
coiled-coil	NULL
region	NULL
and	NULL
PLZF	NULL
POZ	NULL
domain	NULL
are	NULL
not	NULL
entirely	NULL
known	NULL
,	NULL
each	NULL
of	NULL
the	NULL
two	NULL
domains	NULL
is	NULL
capable	NULL
of	NULL
forming	NULL
homo-oligomers	NULL
.	NULL

The	NULL
PML	NULL
coiled-coil	NULL
region	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PML-RARa	NULL
homodimers	NULL
and	NULL
PML-RARa-PML	NULL
heterodimers	NULL
(	NULL
24	NULL
,	NULL
44	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
PLZF	NULL
POZ	NULL
domain	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
PLZF-RARa	NULL
homodimers	NULL
and	NULL
PLZF-RARo-PLZF	NULL
heterodimers	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
identified	NULL
PML-RARa	NULL
mutants	NULL
that	NULL
retain	NULL
the	NULL
capacity	NULL
to	NULL
form	NULL
PML-RARa	NULL
homodimers	NULL
but	NULL
have	NULL
lost	NULL
the	NULL
ability	NULL
to	NULL
form	NULL
heterodimers	NULL
with	NULL
PML	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
these	NULL
mutants	NULL
in	NULL
U937	NULL
cells	NULL
revealed	NULL
that	NULL
the	NULL
competence	NULL
to	NULL
increase	NULL
RA	NULL
sensitivity	NULL
correlates	NULL
with	NULL
that	NULL
of	NULL
forming	NULL
PML-RARa	NULL
«	NULL
homodimers	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
PMLRARa	NULL
homodimers	NULL
might	NULL
have	NULL
a	NULL
more	NULL
potent	NULL
RA-dependent	NULL
enhancer	NULL
function	NULL
than	NULL
,	NULL
in	NULL
myeloid	NULL
cells	NULL
,	NULL
the	NULL
physiological	NULL
RARa-RXR	NULL
heterodimer	NULL
(	NULL
26	NULL
,	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
activity	NULL
of	NULL
PLZF-RARa	NULL
on	NULL
RA	NULL
target	NULL
genes	NULL
might	NULL
instead	NULL
be	NULL
due	NULL
,	NULL
in	NULL
part	NULL
,	NULL
to	NULL
its	NULL
interaction	NULL
with	NULL
POZ-binding	NULL
proteins	NULL
with	NULL
the	NULL
ability	NULL
to	NULL
silence	NULL
transcription	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
POZ-binding	NULL
proteins	NULL
that	NULL
interact	NULL
with	NULL
PLZF	NULL
and	NULL
PLZF-RARa	NULL
might	NULL
help	NULL
in	NULL
clarifying	NULL
this	NULL
issue	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
PML-RARa	NULL
«	NULL
and	NULL
PLZF-RARa	NULL
have	NULL
similar	NULL
inhibitory	NULL
effects	NULL
on	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursor	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
,	NULL
while	NULL
they	NULL
have	NULL
opposite	NULL
effects	NULL
on	NULL
RA	NULL
differentiation	NULL
and	NULL
regulation	NULL
of	NULL
RA	NULL
target	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
pharmacological	NULL
doses	NULL
of	NULL
RA	NULL
.	NULL

These	NULL
results	NULL
might	NULL
explain	NULL
why	NULL
PLZF-RARa	NULL
and	NULL
PML-RARa	NULL
leukemias	NULL
have	NULL
identical	NULL
phenotypes	NULL
but	NULL
opposite	NULL
sensitivities	NULL
to	NULL
RA	NULL
treatment	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Pier	NULL
Paolo	NULL
Di	NULL
Fiore	NULL
,	NULL
Kristian	NULL
Helin	NULL
,	NULL
and	NULL
Giulio	NULL
Dractta	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
AIRC	NULL
,	NULL
CNR	NULL
,	NULL
and	NULL
EC	NULL
4868	NULL
RUTHARDT	NULL
ET	NULL
AL	NULL
.	NULL

(	NULL
Biomed	NULL
and	NULL
Biotech	NULL
)	NULL
.	NULL

Martin	NULL
Ruthardt	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
of	NULL
the	NULL
Dr.	NULL
Mildred-Scheel-Stiftung	NULL
der	NULL
Deutschen	NULL
Krebshilfe	NULL
.	NULL

REFERENCES	NULL
.	NULL

Bardwell	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
Treisman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
POZ	NULL
domain	NULL
:	NULL
a	NULL
conserved	NULL
protein-protein	NULL
interaction	NULL
motif	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

8:1664-1677	NULL
.	NULL

Benedetti	NULL
,	NULL
L.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
B.	NULL
M.	NULL
Scicchit	NULL
A.	NULL
M.	NULL
Jetten	NULL
,	NULL
D.	NULL
Diverio	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
C.	NULL
Gambacorti-Passerini	NULL
,	NULL
S.	NULL
Adamo	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Levin	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
and	NULL
C.	NULL
Nervi	NULL
.	NULL

1996	NULL
.	NULL

Retinoid-induced	NULL
differentiation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
involves	NULL
PML/RARa-mediated	NULL
increase	NULL
of	NULL
type	NULL
II	NULL
transglutaminase	NULL
.	NULL

Blood	NULL
87:1939-1950	NULL
.	NULL

2a.Brown	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
Kogan	NULL
,	NULL
E.	NULL
Lagasse	NULL
,	NULL
I.	NULL
Weissman	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
S.	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

Atwater	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Bishop	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
PML/RARa	NULL
transgene	NULL
initiates	NULL
murine	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:2551-2556.	NULL
.	NULL

Chambon	NULL
,	NULL
P.	NULL
1994	NULL
.	NULL

The	NULL
retinoid	NULL
signalling	NULL
pathway	NULL
:	NULL
molecular	NULL
and	NULL
genetic	NULL
analyses	NULL
.	NULL

Semin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:115-125.	NULL
.	NULL

Chen	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
transcriptional	NULL
co-repressor	NULL
that	NULL
inter	NULL
acts	NULL
with	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
.	NULL

Nature	NULL
377:454-457.	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
N.	NULL
J	NULL
.	NULL

Brand	NULL
,	NULL
A.	NULL
Chen	NULL
,	NULL
S.	NULL
J.	NULL
Chen	NULL
,	NULL
J.	NULL
H.	NULL
Tong	NULL
,	NULL
Z.	NULL
Y.	NULL
Wang	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
and	NULL
A.	NULL
Zelent	NULL
.	NULL

1993	NULL
.	NULL

Fusion	NULL
between	NULL
a	NULL
novel	NULL
Kriippel-like	NULL
zinc	NULL
finger	NULL
gene	NULL
and	NULL
retinoic	NULL
acid	NULL
receptor-	NULL
«	NULL
locus	NULL
due	NULL
to	NULL
a	NULL
variant	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
associated	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12	NULL
;	NULL
1161-1167.	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
F.	NULL
Guidez	NULL
,	NULL
P.	NULL
Rousselot	NULL
,	NULL
A.	NULL
Agadir	NULL
,	NULL
S.	NULL
J.	NULL
Chen	NULL
,	NULL
Z.	NULL
Y.	NULL
Wang	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
and	NULL
C.	NULL
Chomienne	NULL
.	NULL

1994	NULL
.	NULL

PLZF/RARa	NULL
fusion	NULL
proteins	NULL
generated	NULL
from	NULL
the	NULL
variant	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
inhibit	NULL
ligand-dependent	NULL
transactivation	NULL
of	NULL
wild-type	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:1178-1182.	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
HL-60	NULL
promyelocytic	NULL
leukaemia	NULL
cell	NULL
line	NULL
:	NULL
prolifera-	NULL
tion	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
cellular	NULL
oncogene	NULL
expression	NULL
Blood	NULL
70:1233-1244.	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
K.	NULL
Robertson	NULL
,	NULL
and	NULL
L.	NULL
Mueller	NULL
.	NULL

1990	NULL
.	NULL

Retinoic-acid	NULL
induced	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
is	NULL
mediated	NULL
directly	NULL
through	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
(	NULL
RARa	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:2154.	NULL
.	NULL

Degos	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
M.	NULL
T.	NULL
Daniel	NULL
,	NULL
R.	NULL
Berger	NULL
,	NULL
H.	NULL
Dombret	NULL
,	NULL
P.	NULL
Fenauxs	NULL
,	NULL
and	NULL
S.	NULL
Castaigne	NULL
.	NULL

1990	NULL
.	NULL

Treatment	NULL
of	NULL
first	NULL
relapse	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
.	NULL

Lancet	NULL
336:1440-1443.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Lavau	NULL
,	NULL
A.	NULL
Marchio	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
PML-RARa	NULL
fusion	NULL
mRNA	NULL
generated	NULL
by	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
encodes	NULL
a	NULL
functionally	NULL
altered	NULL
RARe..	NULL

Cell	NULL
66:675-684	NULL
.	NULL

Dong	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Zhu	NULL
,	NULL
A.	NULL
Reid	NULL
,	NULL
P.	NULL
Strutt	NULL
,	NULL
F.	NULL
Guidez	NULL
,	NULL
H.	NULL
J.	NULL
Zhong	NULL
,	NULL
Z.	NULL
Y.	NULL
Wang	NULL
,	NULL
J.	NULL
Licht	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
Z.	NULL
Chen	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Chen	NULL
.	NULL

1996	NULL
.	NULL

Amino-terminal	NULL
protein-protein	NULL
interaction	NULL
motif	NULL
(	NULL
POZ-domain	NULL
)	NULL
is	NULL
responsible	NULL
for	NULL
activities	NULL
of	NULL
the	NULL
promyelocytic	NULL
leukaemia	NULL
zinc	NULL
finger-retinoic	NULL
acid	NULL
receptor-a	NULL
fusion	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:3624-3629	NULL
.	NULL

Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
G.	NULL
G.	NULL
Maul	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
D.	NULL
Chen	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
and	NULL
R.	NULL
Evans	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
novel	NULL
macromolecular	NULL
structure	NULL
is	NULL
a	NULL
target	NULL
of	NULL
the	NULL
promyelo-cyte-retinoic	NULL
acid	NULL
receptor	NULL
oncoprotein	NULL
.	NULL

Cell	NULL
76:333-343	NULL
.	NULL

12a.Ferrucci	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
F.	NULL
Griynani	NULL
,	NULL
I.	NULL
Nicoletti	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

Pelicci	NULL
.	NULL

Cell	NULL
death	NULL
induction	NULL
by	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
specific	NULL
PML/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Giudez	NULL
,	NULL
F.	NULL
,	NULL
W.	NULL
Huang	NULL
,	NULL
J.	NULL
T.	NULL
Tong	NULL
,	NULL
C.	NULL
Dubois	NULL
,	NULL
N.	NULL
Balitrand	NULL
,	NULL
J.	NULL
Michaux	NULL
,	NULL
P.	NULL
Martiat	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
and	NULL
C.	NULL
Chomienne	NULL
.	NULL

1994	NULL
.	NULL

Poor	NULL
response	NULL
to	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
PLZF/RARa	NULL
AML3	NULL
patient	NULL
.	NULL

Leukaemia	NULL
8:312-314	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
F.	NULL
Ferrucci	NULL
,	NULL
U.	NULL
Testa	NULL
,	NULL
G.	NULL
Talamo	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
A.	NULL
M	NULL
elli	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
C.	NULL
Peschle	NULL
,	NULL
I.	NULL
Nicoletti	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
specific	NULL
PML/RARa	NULL
fusion	NULL
protein	NULL
inhibits	NULL
differentiation	NULL
and	NULL
promotes	NULL
survival	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
.	NULL

Cell	NULL
74:423-431	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
L.	NULL
Longo	NULL
,	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
,	NULL
E.	NULL
Donti	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1994	NULL
.	NULL

Acute	NULL
promyelocytic	NULL
leukaemia	NULL
:	NULL
from	NULL
genetics	NULL
to	NULL
treatment	NULL
.	NULL

Blood	NULL
83:10-25	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
U.	NULL
Testa	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
T.	NULL
Barberi	NULL
,	NULL
R.	NULL
Masciulli	NULL
,	NULL
G.	NULL
Mariani	NULL
,	NULL
C.	NULL
Peschle	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1995	NULL
.	NULL

Promyelocytic	NULL
leukaemia-specific	NULL
PML-retinoic	NULL
acid	NULL
«	NULL
receptor	NULL
fusion	NULL
protein	NULL
interferes	NULL
with	NULL
erythroid	NULL
differentiation	NULL
of	NULL
human	NULL
erythroleukemia	NULL
K562	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

85:440-443	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
U.	NULL
Testa	NULL
,	NULL
D.	NULL
Rogaia	NULL
,	NULL
P.	NULL
F.	NULL
Ferrucci	NULL
,	NULL
P.	NULL
Samoggia	NULL
,	NULL
A.	NULL
Pinto	NULL
,	NULL
D.	NULL
Aldinucci	NULL
,	NULL
V.	NULL
Gelmetti	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
J.	NULL
Seeler	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
I.	NULL
Nicoletti	NULL
,	NULL
C.	NULL
Peschle	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1996	NULL
.	NULL

Effects	NULL
on	NULL
differentiation	NULL
by	NULL
the	NULL
promyelocytic	NULL
leukaemia	NULL
PML/RARa	NULL
protein	NULL
depend	NULL
on	NULL
the	NULL
fusion	NULL
of	NULL
the	NULL
PML	NULL
protein-dimerization	NULL
and	NULL
RAR	NULL
DNA	NULL
binding	NULL
domains	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:4949-4958	NULL
.	NULL

Grisolano	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
R.	NULL
L.	NULL
Wesselschmidt	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Ley	NULL
.	NULL

1996	NULL
.	NULL

Early	NULL
myeloid	NULL
expression	NULL
of	NULL
PML/RARa	NULL
fusion	NULL
gene	NULL
associated	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
(	NULL
APL	NULL
)	NULL
in	NULL
transgenic	NULL
mice	NULL
alters	NULL
myeloid	NULL
development	NULL
.	NULL

Blood	NULL
86	NULL
(	NULL
Suppl	NULL
.	NULL

1	NULL
)	NULL
:4302	NULL
.	NULL

Horlein	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
A.	NULL
M.	NULL
Niiir	NULL
,	NULL
T.	NULL
Heinzel	NULL
,	NULL
J.	NULL
Torchia	NULL
,	NULL
B	NULL
.	NULL

Gloss	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
A.	NULL
Ryan	NULL
,	NULL
Y.	NULL
Kamei	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1995	NULL
.	NULL

Ligand-independent	NULL
repression	NULL
by	NULL
the	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
mediated	NULL
by	NULL
a	NULL
nuclear	NULL
receptor	NULL
co-repressor	NULL
.	NULL

Nature	NULL
377:397-403	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Yu-Chen	NULL
,	NULL
C.	NULL
Shu-Rong	NULL
,	NULL
J.	NULL
Chai	NULL
,	NULL
Z.	NULL
Lin	NULL
,	NULL
J	NULL
.	NULL

Long	NULL
,	NULL
and	NULL
Z.	NULL
Wang	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

1988	NULL
.	NULL

Use	NULL
of	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
72:567-571	NULL
.	NULL

Jetten	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
F.	NULL
Grippo	NULL
,	NULL
and	NULL
C.	NULL
Nervi	NULL
.	NULL

1990	NULL
.	NULL

Isolation	NULL
and	NULL
binding	NULL
characteristics	NULL
of	NULL
nuclear	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

189	NULL
;	NULL
248-255	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
Jr.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
R.	NULL
P.	NULL
Warrel	NULL
,	NULL
Jr.	NULL
,	NULL
S.	NULL
R.	NULL
Frankel	NULL
,	NULL
V.	NULL
V.	NULL
V.	NULL
S.	NULL
Murty	NULL
,	NULL
E.	NULL
Dmitrovsky	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
RARa	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cell	NULL
66:663-674	NULL
.	NULL

Kamei	NULL
,	NULL
Y.	NULL
,	NULL
L.	NULL
Xu	NULL
,	NULL
T.	NULL
Heizel	NULL
,	NULL
J.	NULL
Torchia	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
B	NULL
.	NULL

Gloss	NULL
,	NULL
S.	NULL
C.	NULL
Lin	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
D.	NULL
W.	NULL
Rose	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
CBP	NULL
integrator	NULL
complex	NULL
mediates	NULL
transcriptional	NULL
activation	NULL
and	NULL
AP-1	NULL
inhibition	NULL
by	NULL
nuclear	NULL
receptors	NULL
.	NULL

Cell	NULL
85:403-414	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Perez	NULL
,	NULL
Y.	NULL
Lutz	NULL
,	NULL
C.	NULL
Rochette-Egly	NULL
,	NULL
M.	NULL
P.	NULL
Gaub	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
M.	NULL
Lanotte	NULL
,	NULL
R.	NULL
Berger	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1992	NULL
.	NULL

Structure	NULL
,	NULL
localization	NULL
and	NULL
transcriptional	NULL
properties	NULL
of	NULL
two	NULL
classes	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
fusion	NULL
proteins	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
:	NULL
structural	NULL
similarities	NULL
with	NULL
a	NULL
new	NULL
family	NULL
of	NULL
oncoproteins	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:629-642.	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Leid	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
nuclear	NULL
retinoic	NULL
acid	NULL
receptors	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
,	NULL
p.	NULL
189-238	NULL
.	NULL

In	NULL
R.	NULL
Blom-hoff	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Vitamin	NULL
A	NULL
in	NULL
health	NULL
and	NULL
disease	NULL
.	NULL

Marcel	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
K.	NULL
Umesono	NULL
,	NULL
D.	NULL
J.	NULL
Mangelsdorf	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Retinoid	NULL
X	NULL
receptor	NULL
interacts	NULL
with	NULL
nuclear	NULL
receptors	NULL
in	NULL
retinoic	NULL
acid	NULL
,	NULL
thyroid	NULL
hormone	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
signalling	NULL
.	NULL

Nature	NULL
355:446-449	NULL
.	NULL

Koken	NULL
,	NULL
M.	NULL
H.	NULL
M.	NULL
,	NULL
F.	NULL
Puvio-Dutilleul	NULL
,	NULL
M.	NULL
C.	NULL
Guillemin	NULL
,	NULL
A.	NULL
Viron	NULL
,	NULL
G.	NULL
Cruz-Linares	NULL
,	NULL
N.	NULL
Stuurman	NULL
,	NULL
L.	NULL
de	NULL
Jong	NULL
,	NULL
C.	NULL
Szostecki	NULL
,	NULL
F.	NULL
Calvo	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
E.	NULL
Puvion	NULL
,	NULL
and	NULL
H.	NULL
de	NULL
The	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
alters	NULL
a	NULL
nuclear	NULL
body	NULL
in	NULL
a	NULL
retinoic	NULL
acid-reversible	NULL
fashion	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:1073-1083	NULL
.	NULL

Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
A.	NULL
Horlein	NULL
,	NULL
S.	NULL
Halachmi	NULL
,	NULL
M.	NULL
Brown	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Glass	NULL
.	NULL

1995	NULL
.	NULL

Polarity-specific	NULL
activities	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
determined	NULL
by	NULL
a	NULL
co-repressor	NULL
.	NULL

Nature	NULL
377:451-454	NULL
.	NULL

Le	NULL
Dourain	NULL
,	NULL
B.	NULL
,	NULL
C.	NULL
Zechel	NULL
,	NULL
J.	NULL
M.	NULL
Garnier	NULL
,	NULL
Y.	NULL
Lutz	NULL
,	NULL
L.	NULL
Tora	NULL
,	NULL
B.	NULL
Pierrat	NULL
,	NULL
D.	NULL
Heery	NULL
,	NULL
H.	NULL
Gronemeyer	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
R.	NULL
Losson	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
N-terminal	NULL
part	NULL
of	NULL
TIF-1	NULL
,	NULL
a	NULL
putative	NULL
mediator	NULL
of	NULL
the	NULL
ligand-dependent	NULL
activation	NULL
function	NULL
(	NULL
AF-2	NULL
)	NULL
of	NULL
nuclear	NULL
receptors	NULL
,	NULL
is	NULL
fused	NULL
to	NULL
B-raf	NULL
in	NULL
the	NULL
oncogenic	NULL
protein	NULL
T18	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:2020-2033	NULL
.	NULL

Lee	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
F.	NULL
Ryan	NULL
,	NULL
J.	NULL
C.	NULL
Swaffield	NULL
,	NULL
S.	NULL
A.	NULL
Johnston	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Moore	NULL
.	NULL

1995	NULL
.	NULL

Interaction	NULL
of	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
with	NULL
a	NULL
conserved	NULL
transcriptional	NULL
mediator	NULL
.	NULL

Nature	NULL
374:91-94	NULL
.	NULL

Licht	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
C.	NULL
Chomienne	NULL
,	NULL
A.	NULL
Goy	NULL
,	NULL
A.	NULL
Chen	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Scott	NULL
,	NULL
D.	NULL
R.	NULL
Head	NULL
,	NULL
J.	NULL
L.	NULL
Michaux	NULL
,	NULL
Y.	NULL
Wu	NULL
,	NULL
A	NULL
.	NULL

De	NULL
Blasio	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
Jr.	NULL
,	NULL
A.	NULL
D.	NULL
Zelenetz	NULL
,	NULL
C.	NULL
L.	NULL
Willman	NULL
,	NULL
Z.	NULL
Chen	NULL
,	NULL
S.	NULL
J.	NULL
Chen	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
E.	NULL
Macintyre	NULL
,	NULL
A.	NULL
Veil	NULL
,	NULL
J.	NULL
Cortes	NULL
,	NULL
H.	NULL
Kantarjian	NULL
,	NULL
and	NULL
S.	NULL
Waxman	NULL
.	NULL

1995	NULL
.	NULL

Clinical	NULL
and	NULL
molecular	NULL
characterisation	NULL
of	NULL
a	NULL
rare	NULL
syndrome	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
associated	NULL
with	NULL
translocation	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
.	NULL

Blood	NULL
85:1083-1094	NULL
.	NULL

Licht	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
Shaknovich	NULL
,	NULL
M.	NULL
A.	NULL
English	NULL
,	NULL
A.	NULL
Melnick	NULL
,	NULL
J.-Y	NULL
.	NULL

Li	NULL
,	NULL
J.	NULL
C.	NULL
Reddy	NULL
,	NULL
S.	NULL
Dong	NULL
,	NULL
S.	NULL
J.	NULL
Chen	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
and	NULL
S.	NULL
Waxman	NULL
.	NULL

1996	NULL
.	NULL

Reduced	NULL
and	NULL
altered	NULL
DNA-binding	NULL
and	NULL
transcriptional	NULL
properties	NULL
of	NULL
the	NULL
PLZF-retinoic	NULL
acid	NULL
receptor-a	NULL
chimera	NULL
generated	NULL
in	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
-associated	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

Oncogene	NULL
12:323-336	NULL
.	NULL

LoCoco	NULL
,	NULL
F.	NULL
,	NULL
G.	NULL
Avvisati	NULL
,	NULL
D.	NULL
Diverio	NULL
,	NULL
M.	NULL
C.	NULL
Petti	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
A.	NULL
Rambaldi	NULL
,	NULL
M.	NULL
L.	NULL
Moleti	NULL
,	NULL
F.	NULL
Mandelli	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1991	NULL
.	NULL

Molecular	NULL
evaluation	NULL
of	NULL
response	NULL
to	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
therapy	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

Blood	NULL
77:1657-1659	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
RXR	NULL
heterodimers	NULL
and	NULL
orphan	NULL
receptors	NULL
.	NULL

Cell	NULL
83:841-850	NULL
.	NULL

Mendelsohn	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Ruberte	NULL
,	NULL
M.	NULL
LeMeur	NULL
,	NULL
G.	NULL
Morris-Kay	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1991	NULL
.	NULL

Developmental	NULL
analysis	NULL
of	NULL
the	NULL
retinoic	NULL
acid-inducible	NULL
RARB2	NULL
promoter	NULL
in	NULL
transgenic	NULL
animals	NULL
.	NULL

Development	NULL
113:723-734	NULL
.	NULL

Minucci	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
K.	NULL
Ozato	NULL
.	NULL

1996	NULL
.	NULL

Retinoid	NULL
receptors	NULL
in	NULL
transcriptional	NULL
reg-ulation	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

6:567-574	NULL
.	NULL

Mitelman	NULL
,	NULL
F.	NULL
1988	NULL
.	NULL

Catalogue	NULL
of	NULL
chromosome	NULL
aberrations	NULL
in	NULL
cancer	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Alan	NULL
R.	NULL
Liss	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Nagpal	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Saunders	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
H.	NULL
Nakshatri	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1992	NULL
.	NULL

Promoter	NULL
context-	NULL
and	NULL
response	NULL
element-dependent	NULL
specificity	NULL
of	NULL
the	NULL
transcriptional	NULL
activation	NULL
and	NULL
modulating	NULL
functions	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Cell	NULL
70:1007-1019	NULL
.	NULL

Nervi	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
E.	NULL
Poindexter	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
P.	NULL
P.	NULL
Pandolfi	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
G.	NULL
Avvisati	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Jetten	NULL
.	NULL

1992	NULL
.	NULL

Characterisation	NULL
of	NULL
the	NULL
PML/RARa	NULL
chimeric	NULL
product	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukaemia-specific	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

52:3687-3692	NULL
.	NULL

Olsson	NULL
,	NULL
I.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Breitman	NULL
.	NULL

1982	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
histiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
U-937	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
cyclic	NULL
adenosine	NULL
3':5'-monophosphate-inducing	NULL
agents	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

42:3924-3927	NULL
.	NULL

Onate	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
S.	NULL
Y.	NULL
Tsai	NULL
,	NULL
M.	NULL
J.	NULL
Tsai	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
O'Malley	NULL
.	NULL

1995	NULL
.	NULL

Sequence	NULL
and	NULL
characterisation	NULL
of	NULL
a	NULL
coactivator	NULL
for	NULL
the	NULL
steroid	NULL
hormone	NULL
receptor	NULL
superfam-ily	NULL
.	NULL

Science	NULL
270:1354-1357	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
A.	NULL
Mencarelli	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1991	NULL
.	NULL

Structure	NULL
and	NULL
origin	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RARa	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retin-oid-binding	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
6:1285-1292	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
D.	NULL
Zangrilli	NULL
,	NULL
A.	NULL
Mencarelli	NULL
,	NULL
D.	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

Diverio	NULL
,	NULL
A.	NULL
Biondi	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
A.	NULL
Rambaldi	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
C.	NULL
Rochette-Egly	NULL
,	NULL
M.	NULL
P.	NULL
Gaube	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Pelicci	NULL
.	NULL

1992	NULL
.	NULL

Genomic	NULL
variability	NULL
and	NULL
alternative	NULL
splicing	NULL
generate	NULL
multiple	NULL
PML-RARa	NULL
transcripts	NULL
that	NULL
encode	NULL
aberrant	NULL
PML	NULL
proteins	NULL
and	NULL
PML/RARa	NULL
isoforms	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:1397-1407	NULL
.	NULL

Perez	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
S.	NULL
Sethi	NULL
,	NULL
Y.	NULL
Lutz	NULL
,	NULL
C.	NULL
Reibel	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1993	NULL
.	NULL

PMLRARa	NULL
homodimers	NULL
:	NULL
distinct	NULL
DNA	NULL
binding	NULL
properties	NULL
and	NULL
hetero-dimeric	NULL
interaction	NULL
with	NULL
RXR	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3171-3182	NULL
.	NULL

Robertson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
B.	NULL
Emami	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Collins	NULL
.	NULL

1992	NULL
.	NULL

Retinoic	NULL
acid-resistant	NULL
HL-60R	NULL
cells	NULL
harbour	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
ligand-binding	NULL
domain	NULL
that	NULL
confers	NULL
dominant	NULL
negative	NULL
activity	NULL
.	NULL

Blood	NULL
80:1885-1889	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Smith	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
H.	NULL
Nakshatri	NULL
,	NULL
P.	NULL
Leroy	NULL
,	NULL
J.	NULL
Rees	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
reinoic	NULL
acid	NULL
response	NULL
element	NULL
is	NULL
present	NULL
in	NULL
the	NULL
mouse	NULL
cellular	NULL
retinol	NULL
binding	NULL
protein	NULL
I	NULL
(	NULL
mCRABP	NULL
I	NULL
)	NULL
promoter	NULL
EMBO	NULL
J	NULL
.	NULL

10:2223-2230	NULL
.	NULL

Testa	NULL
,	NULL
U.	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
T.	NULL
Barberi	NULL
,	NULL
M.	NULL
Fagioli	NULL
,	NULL
R.	NULL
Masciulli	NULL
,	NULL
P.	NULL
F.	NULL
Ferrucci	NULL
,	NULL
D.	NULL
Seripa	NULL
,	NULL
A.	NULL
Camagoa	NULL
,	NULL
M.	NULL
Alcalay	NULL
,	NULL
P.	NULL
G.	NULL
Pelicci	NULL
,	NULL
and	NULL
C.	NULL
Peschle	NULL
.	NULL

1994	NULL
.	NULL

PML/RARa+	NULL
U937	NULL
mutant	NULL
and	NULL
NB4	NULL
cell	NULL
lines	NULL
:	NULL
retinoic	NULL
acid	NULL
restores	NULL
the	NULL
monocytic	NULL
differentiation	NULL
response	NULL
to	NULL
vitamin	NULL
D3	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:4508-4515	NULL
.	NULL

EFFECTS	NULL
OF	NULL
AND	NULL
PLZF-RAR	NULL
«	NULL
ON	NULL
RA	NULL
DIFFERENTIATION	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

4869	NULL
Vom	NULL
Baur	NULL
,	NULL
E.	NULL
,	NULL
C.	NULL
Zechel	NULL
,	NULL
D.	NULL
Heery	NULL
,	NULL
M.	NULL
J.	NULL
S.	NULL
Heine	NULL
,	NULL
J.	NULL
M.	NULL
Garnier	NULL
,	NULL
V.	NULL
Vivat	NULL
,	NULL
B	NULL
.	NULL

Le	NULL
Dourain	NULL
,	NULL
H.	NULL
Gronemeyer	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
and	NULL
R.	NULL
Losson	NULL
.	NULL

1996	NULL
.	NULL

Differential	NULL
ligand-dependent	NULL
interactions	NULL
between	NULL
the	NULL
AF-2	NULL
activating	NULL
domain	NULL
of	NULL
nuclear	NULL
receptors	NULL
and	NULL
the	NULL
putative	NULL
transcriptional	NULL
intermediary	NULL
factors	NULL
mSUG1	NULL
and	NULL
TIFL	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:110-124	NULL
.	NULL

Warrel	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
S.	NULL
R.	NULL
Frankel	NULL
,	NULL
W.	NULL
H.	NULL
Miller	NULL
,	NULL
D.	NULL
A.	NULL
Scheinberg	NULL
,	NULL
L.	NULL
M.	NULL
Itri	NULL
,	NULL
W.	NULL
N.	NULL
Hittelman	NULL
,	NULL
R.	NULL
Vyas	NULL
,	NULL
M.	NULL
Andreeff	NULL
,	NULL
A.	NULL
Tafuri	NULL
,	NULL
A.	NULL
Jakubowski	NULL
,	NULL
J.	NULL
Gabrilove	NULL
,	NULL
M.	NULL
S.	NULL
Gordon	NULL
,	NULL
and	NULL
E.	NULL
Dmitrovsky	NULL
.	NULL

1991	NULL
.	NULL

Differentiation	NULL
therapy	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
)	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

324:1358-1393	NULL
.	NULL

Warrel	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
H.	NULL
de	NULL
Thé	NULL
,	NULL
Z.	NULL
Y.	NULL
Wang	NULL
,	NULL
and	NULL
L.	NULL
Degos	NULL
.	NULL

1993	NULL
.	NULL

Acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

329:177-189	NULL
.	NULL

Weis	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Rambaud	NULL
,	NULL
C.	NULL
Lavau	NULL
,	NULL
J.	NULL
Jansen	NULL
,	NULL
T.	NULL
Carcalho	NULL
,	NULL
M.	NULL
Carmo-Fonseca	NULL
,	NULL
A.	NULL
Lamond	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1994	NULL
.	NULL

Retinoic	NULL
acid	NULL
regulates	NULL
aberrant	NULL
nuclear	NULL
localisation	NULL
of	NULL
PML-RARa	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
cells	NULL
.	NULL

Cell	NULL
76:345-358	NULL
.	NULL

Yu	NULL
,	NULL
V.	NULL
C.	NULL
,	NULL
C.	NULL
Delsert	NULL
,	NULL
B.	NULL
Andersen	NULL
,	NULL
J.	NULL
M.	NULL
Holloway	NULL
,	NULL
O.	NULL
V.	NULL
Devary	NULL
,	NULL
A.	NULL
M.	NULL
Naar	NULL
,	NULL
S.	NULL
Y.	NULL
Kim	NULL
,	NULL
J.	NULL
M.	NULL
Boutin	NULL
,	NULL
C.	NULL
K.	NULL
Glass	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1991	NULL
.	NULL

RXRB	NULL
:	NULL
a	NULL
coregulator	NULL
that	NULL
enhances	NULL
binding	NULL
of	NULL
retinoic	NULL
acid	NULL
,	NULL
thyroid	NULL
hormone	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
receptors	NULL
to	NULL
their	NULL
cognate	NULL
response	NULL
elements	NULL
.	NULL

Cell	NULL
67:1251-1266	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
K.	NULL
,	NULL
B.	NULL
Hoffmann	NULL
,	NULL
P.	NULL
B.	NULL
V.	NULL
Tran	NULL
,	NULL
G.	NULL
Graupner	NULL
,	NULL
and	NULL
M.	NULL
Pfahl	NULL
.	NULL

1992	NULL
.	NULL

Retinoid	NULL
X	NULL
receptor	NULL
is	NULL
an	NULL
auxiliary	NULL
protein	NULL
for	NULL
thyroid	NULL
hormone	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Nature	NULL
355:441-446	NULL
.	NULL

